ZA200605158B - Proteins - Google Patents
Proteins Download PDFInfo
- Publication number
- ZA200605158B ZA200605158B ZA2006/05158A ZA200605158A ZA200605158B ZA 200605158 B ZA200605158 B ZA 200605158B ZA 2006/05158 A ZA2006/05158 A ZA 2006/05158A ZA 200605158 A ZA200605158 A ZA 200605158A ZA 200605158 B ZA200605158 B ZA 200605158B
- Authority
- ZA
- South Africa
- Prior art keywords
- seq
- enzyme
- amino acid
- variant
- sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 111
- 102000004169 proteins and genes Human genes 0.000 title claims description 92
- 102000004190 Enzymes Human genes 0.000 claims abstract description 259
- 108090000790 Enzymes Proteins 0.000 claims abstract description 259
- 230000000694 effects Effects 0.000 claims abstract description 256
- 150000002632 lipids Chemical class 0.000 claims abstract description 212
- 108700016155 Acyl transferases Proteins 0.000 claims abstract description 196
- 102000057234 Acyl transferases Human genes 0.000 claims abstract description 184
- 150000001413 amino acids Chemical class 0.000 claims abstract description 173
- 238000000034 method Methods 0.000 claims abstract description 168
- 102000004357 Transferases Human genes 0.000 claims abstract description 147
- 108090000992 Transferases Proteins 0.000 claims abstract description 147
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 92
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 89
- 239000000758 substrate Substances 0.000 claims abstract description 69
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 58
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 58
- 230000004048 modification Effects 0.000 claims abstract description 56
- 238000012986 modification Methods 0.000 claims abstract description 56
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 47
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 43
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 36
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 33
- 238000012360 testing method Methods 0.000 claims abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 125
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 99
- 125000003729 nucleotide group Chemical group 0.000 claims description 99
- FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 claims description 68
- -1 carbohydrate esters Chemical class 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 150000002148 esters Chemical class 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 230000002366 lipolytic effect Effects 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 21
- 239000002446 δ-tocopherol Substances 0.000 claims description 18
- 230000002255 enzymatic effect Effects 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 17
- 235000019198 oils Nutrition 0.000 claims description 17
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 16
- 230000007062 hydrolysis Effects 0.000 claims description 16
- 238000006460 hydrolysis reaction Methods 0.000 claims description 16
- 150000003626 triacylglycerols Chemical class 0.000 claims description 14
- QUZHZFAQJATMCA-UHFFFAOYSA-N Monogalactosyldiglyceride Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCC=CCC)COC1OC(CO)C(O)C(O)C1O QUZHZFAQJATMCA-UHFFFAOYSA-N 0.000 claims description 12
- 239000008157 edible vegetable oil Substances 0.000 claims description 10
- 238000013507 mapping Methods 0.000 claims description 10
- 108010001267 Protein Subunits Chemical class 0.000 claims description 8
- 102000002067 Protein Subunits Human genes 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 101100238304 Mus musculus Morc1 gene Proteins 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 222
- 235000001014 amino acid Nutrition 0.000 description 165
- 229940024606 amino acid Drugs 0.000 description 158
- 235000018102 proteins Nutrition 0.000 description 88
- 108090000765 processed proteins & peptides Proteins 0.000 description 85
- 102000004196 processed proteins & peptides Human genes 0.000 description 83
- 229920001184 polypeptide Polymers 0.000 description 79
- 229910052721 tungsten Inorganic materials 0.000 description 75
- 125000002252 acyl group Chemical group 0.000 description 74
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 72
- DQSIEXZABIATEF-UHFFFAOYSA-N 1-(1-adamantyl)-n-methylmethanamine Chemical compound C1C(C2)CC3CC2CC1(CNC)C3 DQSIEXZABIATEF-UHFFFAOYSA-N 0.000 description 59
- 229930182558 Sterol Natural products 0.000 description 53
- 235000003702 sterols Nutrition 0.000 description 53
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 48
- 239000000370 acceptor Substances 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 39
- 150000003432 sterols Chemical class 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 37
- 235000012000 cholesterol Nutrition 0.000 description 33
- 150000004665 fatty acids Chemical class 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 241000607528 Aeromonas hydrophila Species 0.000 description 31
- 235000014633 carbohydrates Nutrition 0.000 description 29
- 235000014113 dietary fatty acids Nutrition 0.000 description 29
- 229930195729 fatty acid Natural products 0.000 description 29
- 239000000194 fatty acid Substances 0.000 description 29
- 235000021588 free fatty acids Nutrition 0.000 description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 26
- 239000013598 vector Substances 0.000 description 26
- 108091035707 Consensus sequence Proteins 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 230000035772 mutation Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 238000012546 transfer Methods 0.000 description 20
- 241000607525 Aeromonas salmonicida Species 0.000 description 19
- 150000001840 cholesterol esters Chemical class 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 229910052700 potassium Inorganic materials 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 235000013601 eggs Nutrition 0.000 description 17
- 150000001720 carbohydrates Chemical class 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 108090001060 Lipase Proteins 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 241001446311 Streptomyces coelicolor A3(2) Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000000787 lecithin Substances 0.000 description 13
- 229940067606 lecithin Drugs 0.000 description 13
- 235000010445 lecithin Nutrition 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 241000233866 Fungi Species 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 12
- 102000004882 Lipase Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 102000045404 acyltransferase activity proteins Human genes 0.000 description 11
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 239000004367 Lipase Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 235000019421 lipase Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 8
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 8
- 102220484246 Replication stress response regulator SDE2_E309A_mutation Human genes 0.000 description 8
- 241000187747 Streptomyces Species 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 108010004211 glycerophospholipid-cholesterol acyltransferase Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000228212 Aspergillus Species 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 7
- 235000008429 bread Nutrition 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 6
- 102220496136 5-hydroxytryptamine receptor 3B_K22A_mutation Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 6
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 102100027441 Nucleobindin-2 Human genes 0.000 description 6
- 102220502675 Post-GPI attachment to proteins factor 4_N87A_mutation Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 101710187798 60S ribosomal protein L23 Proteins 0.000 description 5
- 241000607534 Aeromonas Species 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 102220598064 Cell division cycle and apoptosis regulator protein 1_N88A_mutation Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 102220214525 rs1060502897 Human genes 0.000 description 5
- 102220258069 rs935976612 Human genes 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 102220626037 Bestrophin-1_K82A_mutation Human genes 0.000 description 4
- 241000186216 Corynebacterium Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 102220467931 HLA class II histocompatibility antigen, DP beta 1 chain_G40L_mutation Human genes 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241000232299 Ralstonia Species 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 241000187432 Streptomyces coelicolor Species 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 102220476468 Immunoglobulin heavy constant gamma 3_Y226F_mutation Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000383839 Novosphingobium Species 0.000 description 3
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 108010043958 Peptoids Proteins 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000235346 Schizosaccharomyces Species 0.000 description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 3
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 3
- 241000187419 Streptomyces rimosus Species 0.000 description 3
- 102220506896 Taste receptor type 2 member 9_Y30F_mutation Human genes 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000001261 hydroxy acids Chemical class 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- LPZCCMIISIBREI-JXMPMKKESA-N (Z)-24-ethylidenelophenol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 LPZCCMIISIBREI-JXMPMKKESA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- CCBGJZIXYONESN-UHFFFAOYSA-N 6-(dihydroxymethyl)-6-hydroxy-2h-pyran-5-one Chemical compound OC(O)C1(O)OCC=CC1=O CCBGJZIXYONESN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 101710175493 GDSL lipase Proteins 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000589771 Ralstonia solanacearum Species 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102220484483 Ribonuclease H2 subunit C_T3S_mutation Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241001468227 Streptomyces avermitilis Species 0.000 description 2
- 102220578297 Sulfite oxidase, mitochondrial_G40Q_mutation Human genes 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 102220506906 Taste receptor type 2 member 9_Y30A_mutation Human genes 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000607493 Vibrionaceae Species 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220346513 c.241C>G Human genes 0.000 description 2
- 102220353116 c.40G>A Human genes 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009884 interesterification Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- FPBHSTHTCPCNBS-QXMYDWGFSA-N methyl N-[(E)-5-[4-hydroxy-5-[(2E,4E,9E,12E)-8-hydroxy-2,5,9-trimethyltetradeca-2,4,9,12-tetraenoyl]-6-oxopyran-2-yl]hex-1-enyl]carbamate Chemical compound COC(=O)N\C=C\CCC(C)C1=CC(O)=C(C(=O)C(\C)=C\C=C(/C)CCC(O)C(\C)=C\C\C=C\C)C(=O)O1 FPBHSTHTCPCNBS-QXMYDWGFSA-N 0.000 description 2
- FUJVJJBVXLPRQJ-UHFFFAOYSA-N microthecin Chemical compound OCC1(O)OCC=CC1=O FUJVJJBVXLPRQJ-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical compound NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 2
- 229940075999 phytosterol ester Drugs 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102220083962 rs370887726 Human genes 0.000 description 2
- 102220089470 rs879255591 Human genes 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- STLJXSQSUAPXFX-UHFFFAOYSA-N (10S)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1.5-dimethyl-4-aethyl-hexen-(4)-yl)-(5tH.9tH.14tH)-Delta7-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)=C(C)C)CCC33)C)C3=CCC21 STLJXSQSUAPXFX-UHFFFAOYSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- AZTRKNAMMRCEQJ-BYPYZUCNSA-N (2s)-5,5-dihydroxy-2-(hydroxymethyl)oxan-4-one Chemical compound OC[C@@H]1CC(=O)C(O)(O)CO1 AZTRKNAMMRCEQJ-BYPYZUCNSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- UNFGQCCHVMMMRF-UHFFFAOYSA-N 2-phenylbutanamide Chemical compound CCC(C(N)=O)C1=CC=CC=C1 UNFGQCCHVMMMRF-UHFFFAOYSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
- 241000228215 Aspergillus aculeatus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150096010 CGT gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- JZVFJDZBLUFKCA-ZXLWUMLCSA-N Chondrillasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-ZXLWUMLCSA-N 0.000 description 1
- DBPRUZCKPFOVDV-UHFFFAOYSA-N Clorprenaline hydrochloride Chemical compound O.Cl.CC(C)NCC(O)C1=CC=CC=C1Cl DBPRUZCKPFOVDV-UHFFFAOYSA-N 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 241001509319 Desulfitobacterium Species 0.000 description 1
- 241001509301 Desulfitobacterium dehalogenans Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 101150108358 GLAA gene Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000125500 Hedypnois rhagadioloides Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- 102220475874 Keratin, type I cytoskeletal 10_L17A_mutation Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000970829 Mesorhizobium Species 0.000 description 1
- 241000589195 Mesorhizobium loti Species 0.000 description 1
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000233540 Novosphingobium aromaticivorans Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102220509193 PDZ domain-containing protein 11_L82A_mutation Human genes 0.000 description 1
- 241000194109 Paenibacillus lautus Species 0.000 description 1
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 102220565401 Peptidyl-prolyl cis-trans isomerase FKBP5_N80A_mutation Human genes 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- JZVFJDZBLUFKCA-INYURWPISA-N Poriferasta-7,22E-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-INYURWPISA-N 0.000 description 1
- HCXVJBMSMIARIN-LWINXXIXSA-N Poriferasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-LWINXXIXSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000947836 Pseudomonadaceae Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241001468239 Streptomyces murinus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 241000205091 Sulfolobus solfataricus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000223257 Thermomyces Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000520892 Xanthomonas axonopodis Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241000204366 Xylella Species 0.000 description 1
- 241000204362 Xylella fastidiosa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102220466611 Zinc finger protein GLI1_Y230F_mutation Human genes 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- ZXCYXCIWKAILMP-BYPYZUCNSA-N ascopyrone P Chemical compound OC[C@@H]1CC(=O)C(O)=CO1 ZXCYXCIWKAILMP-BYPYZUCNSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- CCDWGDHTPAJHOA-UHFFFAOYSA-N benzylsilicon Chemical compound [Si]CC1=CC=CC=C1 CCDWGDHTPAJHOA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 102220350724 c.68T>A Human genes 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- QVFWZNCVPCJQOP-UHFFFAOYSA-N chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- BTCAEOLDEYPGGE-JVAZTMFWSA-N episterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 BTCAEOLDEYPGGE-JVAZTMFWSA-N 0.000 description 1
- DNVPQKQSNYMLRS-APGDWVJJSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-APGDWVJJSA-N 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000005254 filamentous fungi cell Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000010037 flour treatment agent Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BTCAEOLDEYPGGE-UHFFFAOYSA-N methylene-24 cholesten-7 ol-3 beta Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(=C)C(C)C)CCC33)C)C3=CCC21 BTCAEOLDEYPGGE-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 102220078387 rs377724143 Human genes 0.000 description 1
- 102220057255 rs730881172 Human genes 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- HCXVJBMSMIARIN-UHFFFAOYSA-N stigmasterol Chemical compound C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 HCXVJBMSMIARIN-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000009263 target vessel revascularization Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
Abstract
The present invention relates to a method of producing a variant glycolipid acyltransferase enzyme comprising: (a) selecting a parent enzyme which is a glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S; (b) modifying one or more amino acids to produce a variant glycolipid acyltransferase; (c) testing the variant glycolipid acyltransferase for transferase activity, an optionally hydrolytic activity, on a galactolipid substrate, and optionally a phospholipid substrate and/or optionally a triglyceride substrate; (d) selecting a variant enzyme with an enhanced activity towards galactolipids compared with the parent enzyme; and optionally (e) preparing a quantity of the variant enzyme. The present invention further relates to variant lipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2, set 4, set 6 or set 7.
Description
PROTEINS
Reference is made to the following related applications: United States Application
Serial Number 09/750,990 filed on 20 July 1999; United States Application Serial
Number 10/409,391; United States Application Serial Number 60/489,441 filed on 23
July 2003; United Kingdom Application Number GB 0330016.7 filed on 24 December 2003 and International Patent Application Number PCT/IB2004/000655 filed on 15
January 2004. Each of these applications and each of the documents cited in each of these applications (“application cited documents”), and each document referenced or cited in the application cited documents, either in the text or during the prosecution of those applications, as well as all arguments in support of patentability advanced during such prosecution, are hereby incorporated herein by reference. Various documents are also cited in this text (“herein cited documents”). Each of the herein cited documents, and each document cited or referenced in the herein cited documents, is hereby incorporated herein by reference.
The present invention relates to methods of producing variant enzymes. The present invention further relates to novel variant enzymes and to the use of these novel variant enzymes.
Lipid:cholesterol acyltransferase enzymes have been known for some time (see for example Buckley - Biochemistry 1983, 22, 5490-5493). In particular, glycerophospholipid:cholesterol acyl transferases (GCATs) have been found, which like the plant and/or mammalian lecithin:cholesterol acyltransferases (LCATSs), will catalyse fatty acid transfer between phosphatidylcholine and cholesterol.
Upton and Buckley (TIBS 20, May 1995, p178-179) and Brumlik and Buckley (J. of
Bacteriology Apr. 1996, p2060-2064) teach a lipase/acyltransferase from Aeromonas hydrophila which has the ability to carry out acyl transfer to alcohol receptors in aqueous media.
A putative substrate binding domain and active site of the A. hydrophila acyltransferase have been identified (see for example Thornton ef al 1988 Biochem. et
Biophys. Acta. 959, 153-159 and Hilton & Buckley 1991 J. Biol. Chem. 266, 997- 1000) for this enzyme.
Buckley et al (J. Bacteriol 1996, 178(7) 2060-4) taught that Ser16, Asp116 and His291 are essential amino acids which must be retained for enzyme activity to be maintained.
Robertson ef al (J. Biol. Chem. 1994, 269, 2146-50) taught some specific mutations, namely Y226F, Y230F, Y30F, F13S, S18G, S18V, of the A. hydrophila acyltransferase, none of which are encompassed by the present invention.
The present invention is predicated upon the finding of specific variants of a GDSx containing lipid acyltransferase enzyme, which variants have an increased transferase activity compared with a parent enzyme. In particular, the variants according to the present invention have an enhanced transferase activity using galactolipid as an acyl donor as compared with a parent enzyme. These lipid acyltransferases are referred to herein as glycolipid acyltransferases. The variants according to the present invention may additionally have an enhanced ratio of transferase activity using galactolipids as an acyl donor as compared with phospholipid transferase activity (GL:PL ratio) and/or an enhanced ratio of transferse activity using galactolipids as an acyl donor as compared with galactolipid hydrolysis activity (GLt:GLh ratio) compared with a parent enzyme.
According to a first aspect the present invention provides a method of producing a variant glycolipid acyltransferase enzyme comprising: (a) selecting a parent enzyme which is a lipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V,LF, Y, H, Q,T,N,MorS; (b) modifying one or more amino acids to produce a variant lipid acyltransferase; (c) testing the variant lipid acyltransferase for activity on a galactolipid substrate, and optionally a phospholipid substrate and/or optionally a triglyceride substrate; (d) selecting a variant enzyme with an enhanced activity towards galactolipids compared with the parent enzyme; and optionally (¢) preparing a quantity of the variant enzyme.
In another aspect the present invention provides a variant glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif
GDSX, wherein X is one or more of the following amino acid residues LA V,LF,
Y,H,QT,N,MorsS, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (defined hereinbelow).
In a further aspect the present invention provides a variant glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif
GDSX, wherein X is one or more of the following amino acid residues L, A, V, LF,
Y,H,Q T,N,MorS5, and wherein the variant enzyme comprises one or more amino "acid modifications compared with a parent sequence at any one Or more of the amino acid residues detailed in set 2 or set 4 or set 6 or set 7 (defined hereinbelow) identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught herein.
The present invention yet further provides a variant glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V,L F, Y, H, Q,
T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 1) and modified according to a structural model of
P10480 to ensure best fit overlap (see Figure 55) as taught
According to a further aspect the present invention provides a variant glycolipid acyltransferase enzyme wherein the variant enzyme comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26,
SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36,
SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43, or SEQ ID No. 45 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (hereinafter defined) identified by sequence alignment with SEQ ID No. 2.
In a further aspect the present invention provides a variant glycolipid acyltransferase enzyme wherein the variant enzyme comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18,
SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28,
SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37,
SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45 except for one or more amino acid modifications at any one or more of the amino acid residues defined 75 in set 2 or set 4 or set 6 or set 7 identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught herein.
According to a further aspect the present invention provides a variant glycolipid acyltransferase enzyme wherein the variant enzyme: comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26,
SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36,
SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45 5 except for one or more amino acid modifications at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 1) and modified according to a structural model of
P10480 to ensure best fit overlap (see Figure 55) as taught
The present invention yet further provides the use of a variant glycolipolytic enzyme according to the present invention or obtained by a method according to the present invention in the manufacture of a substrate (preferably a foodstuff) to prepare a lyso- glycolipid, for example digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG) by treatment of a glycolipid (e.g. digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDQ)) with the variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention to produce the partial hydrolysis product, i.e. the lyso-glycolipid.
In a further aspect, the present invention provides the use of a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention in the manufacture of a substrate (preferably a foodstuff) to prepare a lyso- phospholipid, for example lysolecithin, by treatment of a phospholipid (e.g. lecithin) with the variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention to produce a partial hydrolysis product, i.e a lyso-phospholipid.
In one aspect the present invention relates to a method of preparing a foodstuff the method comprising adding a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention to one or more ingredients of the foodstuff.
Another aspect of the present invention relates to a method of preparing a baked product from a dough, the method comprising adding a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention to the dough.
In another aspect of the present invention there is provided the use of a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention in the manufacture of an egg-based product for producing lysophospholipids.
In another aspect, there is provided a method of treating eggs or egg-based products comprising adding a variant lipolytic enzyme according to the present invention to an egg or an egg-based product to produce a lysophospbolipid.
The variants of the invention may be used in a process of production of a snack food such as instant noodles in analogy with WO002/065854.
The present invention relates to the use of the variant lipid acyltransferase in accordance with the present invention to results in a preferred technical effect or combination of technical effects in for example the foodstuff (such as those listed herein under ‘Technical Effects’).
A further aspect of the present invention provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a variant lipolytic enzyme according to the present invention or obtained by a method : according to the present invention so as to hydrolyse a major part of the polar lipids (e.g. phospholipid and/or glycolipid).
In another aspect the present invention provides a process comprising treating a phospholipid so as to hydrolyse fatty acyl groups, which process comprising admixing said phospholipids with a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention.
Tn another aspect the present invention provides a process of reducing the content of a phospholipid in an edible oil, comprising treating the oil with a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention so as to hydrolyse a major part of the phospholipid, and separating an aqueous phase containing the hydrolysed phospholipid from the oil.
There is also provided a method of preparing a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention, the method comprising transforming a host cell with a recombinant nucleic acid comprising a nucleotide sequence coding for said variant lipolytic enzyme, the host cell being capable of expressing the nucleotide sequence coding for the polypeptide of the lipolytic enzyme, cultivating the transformed host cell under conditions where the nucleic acid is expressed and harvesting the variant lipolytic enzyme.
In a further aspect the present invention relates to the use of a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention in the bioconversion of polar lipids (preferably glycolipids) to make high value products, such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
A method of bioconverting polar lipids (preferably glycolipids) to high value products, which method comprises admixing said polar lipid with a variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention.
The present invention yet further relates to an immobilised variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention.
Aspects of the present invention are presented in the claims and in the following commentary.
Other aspects concerning the nucleotide sequences which can be used in the present invention include: a construct comprising the sequences of the present invention; a vector comprising the sequences for use in the present invention; a plasmid comprising the sequences for use in the present invention; a transformed cell comprising the sequences for use in the present invention; a transformed tissue comprising the : sequences for use in the present invention; a transformed organ comprising the sequences for use in the present invention; a transformed host comprising the sequences for use in the present invention; a transformed organism comprising the sequences for use in the present invention. The present invention also encompasses methods of expressing the nucleotide sequence for use in the present invention using the same, such as expression in a host cell; including methods for transferring same.
The present invention further encompasses methods of isolating the nucleotide sequence, such as isolating fromahostcell.
Other aspects concerning the amino acid sequence for use in the present invention include: a construct encoding the amino acid sequences for use in the present invention; a vector encoding the amino acid sequences for use in the present invention; a plasmid encoding the amino acid sequences for use in the present invention; a transformed cell expressing the amino acid sequences for use in the present invention; a transformed tissue expressing the amino acid sequences for use in the present invention; a transformed organ expressing the amino acid sequences for use in the present invention; a transformed host expressing the amino acid sequences for use in the present invention; a transformed organism expressing the amino acid sequences for use in the present invention. The present invention also encompasses methods of purifying the amino acid sequence for use in the present invention using the same, such as expression in a host cell; including methods of transferring same, and then purifying said sequence.
For the ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
DEFINITION OF SETS
: Amino acid set 1:
Amino acid set 1 (note that these are amino acids in 1TVN — Figure 57 and Figure 58.)
Gly8 Serl0, Leull, Serl2, Tyrl5, Gly44, Asp45, Thrd6, Glu69, Leu70, Gly71,
Gly72, 73. Asp74, Gly75, Leu76, Glnl06, Te107, Argl08, Leul09, Prol 10,
Tyr113, Phel21, Phel39, Phe140, Met141, Tyr145, Met151, Aspl54, His157, Glyl55,
TIlel56, ProlS8
The highly conserved motifs, such as GDSx and catalytic residues, were deselected from set 1 (residues underlined). For the avoidance of doubt, set 1 defines the amino acid residues within 10A of the central carbon atom of a glycerol in the active site of the 1IVN model.
Amino acid set 2:
Amino acid set 2 (note that the numbering of the amino acids refers to the amino acids in the P10480 mature sequence)
Leul7, Lys22, Met23, Gly40, Asn80, Pro8l, Lys82, Asn87, Asn88, Trpl1l, Valll2,
Alall4, Tyrll7, Leul18, Prol56, Gly159, Gln160, Asnl61, Pro162, Ser163, Alalé4,
Argl65, Serl66, GIn167, Lys168, Val169, Val170, Glul71, Alal72, Tyr179, His180,
Asnl81, Met209, Leu210, Arg211, Asn215, Lys284, Met285, GIn289 and Val290.
Table of selected residues in Set 1 compared with Set 2:
IVN model P10480
Mature sequence Residue
IVN A.hyd homologue | Number
I Ld
+ | Asp9 Asp33
Serl0 | Ser34
Leull |Leu35 Leul?7
Ser12 | Ser36 Ser18
Lys22
Met23
Tyrl5 | Gly58 Gly40
Gly44 | Asn98 Asn80
Asp45 | Pro%9 Pro81
Thr46 | Lys100 Lys82
Asn87
Asn88
Glu69 | Trpl29 Trplll
Leu70 | Vall30 Valll2
Gly71 | Gly13l
Gly72 | Alal132 Alall4
Asn73 | Asnl33
Asp74 | Aspl34
Gly75 | Tyrl35 Tyrll7
Leu76 |Leul36 Leull8
GIn106 Prol74 Prol56
Ile107 Gly177 Gly159
Argl08 GIn178 GIn160
Leul09 Asnl79 Asnl61
Pro110 180 to 190 | Prol62
Tyrl13 Ser163
Alal64
Argl65
Ser166
Gln167
Lys168
Vall69
Vall70
Ghul?
Alal72
Phel21 | His198 | Tyrl97 Tyrl79
His198 | His180
Asnl99 Asnl81
Phe139 | Met227 Met209
Phel40 | Leu228 Leu210
Met141 | Arg229 Arg21l
Tyr145 | Asn233 Asn215
Lys284
Met151 | Met303 Met285
Aspl54 | Asp306
Gly155 | GIn307 GIn289 l e156 | Val308 Val290
His157 | His309
Pro158 | Pro310
Amino acid set 3:
Amino acid set 3 is identical to set 2 but refers to the Aeromonas salmonicida (SEQ ID
No. 28) coding sequence, i.e. the amino acid residue numbers are 18 higher in set 3 as this reflects the difference between the amino acid numbering in the mature protein (SEQ ID No. 2) compared with the protein including a signal sequence (SEQ ID No.
The mature proteins of Aeromonas salmonicida GDSX (SEQ ID No. 28) and
Aeromonas hydrophila GDSX (SEQ ID No. 26) differ in five amino acids. These are
Thr3Ser, Gin182Lys, Glu309Ala, Ser310Asn, Gly318-, where the salmonicida residue is listed first and the hydrophila residue is listed last (FIGURE 59). The hydrophila protein is only 317 amino acids long and lacks a residue in position 318. The
Aeromonas salmonicidae GDSX has consjderably high activity on polar lipids such as galactolipid substrates than the Aeromonas hydrophila protein. Site scanning was performed on all five amino acid positions.
Amino acid set 4:
Amino acid set 4 is S3, Q182, E309, S310, and -318.
Amino acid set 5:
F138, D15N, S18G, S18V, Y30F, D116N, D116E, D157 N, Y226F, D228N Y230F.
Amino acid set 6:
Amino acid set 6 is Ser3, Leul7, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87,
Asn88, Trplll, Vall12, Alal14, Tyr117, Leul 18, Prol56, Gly159, GIn160, Asnl61,
Prol62, Ser163, Alal64, Argl65, Ser166, Gln167, Lys168, Vall69, Vall170, Glul71,
Alal72, Tyrl79, His180, Asnl8l, GInl82, Met209, Leu210, Arg2l1l, Asn21S,
Lys284, Met285, GIn289, Val290, Glu309, Ser310, -318.
The numbering of the amino acids in set 6 refers to the amino acids residues in P10480 (SEQ ID No. 2) — corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1TVN.
Amino acid set 7:
Amino acid set 7 is Ser3, Leul7, Lys22, Met23, Gly40, Asn80, Pro8l, Lys82, Asn 87,
Asn88, Trp111, Vall12, Alall4, Tyr117, Leul18, Prol56, Glyl 59, Gln160, Asnl6l, Prol62, Ser163, Alal64, Argl6s, Ser166, Gln167, Lys168, Vall69, Val170, Glul71,
Alal72, Tyrl79, His180, Asnl8l, Gin182, Met209, Leu210, Arg2ll, Asn215,
Lys284, Met285, GIn289, Val290, Glu309, Ser310, -318, Y30X (where X is selected from A, C, D,E, GH, LK, L, M,N, P, QRS, T, V, or W), Y226X (where X is selected from A, C,D,E,G, HL LK, L, M,N, P,Q, R, S, T, V, or W), Y230X (where
X is selected from A, C,D, E, G, H, I, KLMNPQRSTV,or Ww), S18X (where X is selected from A, C, D, E,F,H LK LMNPQRT Wor Y), D157X (where X is selected from A, C, E, F,G,HL LK LMPQR,STYV, WorY).
The numbering of the amino acids in set 7 refers to the amino acids residues in P10480 (SEQ ID No. 2) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN).
Preferably, the parent lipid acyltransferase enzyme comprises any one of the following amino acid sequences: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5,
SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ
ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID
No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45 or an amino acid sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ
ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID
No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No.
34, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45.
Suitably, the parent lipid acyltransferase enzyme according to the present invention comprises an amino acid sequence which has at least 80%, preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more at least 98% homology with any one of the sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26,
SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36,
SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45.
Suitably, the parent lipid acyltransferase enzyme may be encoded by any one of the following nucleotide sequences: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID
No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29,
SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40,
SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46 or a nucleotide sequence which has at least 75% or more identity with any one of the sequences shown as SEQ ID No. 7,
SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ
ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID
No. 25, SEQ ID No.27, SEQ ID No. 29, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46.
Suitably, the nucleotide sequence may have 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 98% or more identity with any one of the sequences shown as SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID
No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29,
SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40,
SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46.
Preferably, the parent enzyme is modified at one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 when aligned to the reference sequence (SEQ
ID No. 2) or structurally aligned to the structural model of P10480, or aligned to the pfam consensus sequence and modified according to the structural model of P10480.
Suitably the variant enzyme may have an enhanced ratio of activity on galactolipids compared with the activity on either phospholipids and/or triglycerides when compared with the parent enzyme.
Suitably, the method according to the present invention may comprise testing the variant lipid acyltransferase for: (i) transferase activity from a galactolipid substrate, and (ii) transferase activity from a phospholipids substrate; and selecting a variant enzyme, which when compared with the parent enzyme, has an enhanced ratio of transferase activity from galactolipids compared with phospholipids.
Suitably, the ratio of transferase activity from galactolipids compared with phospholipids of the variant enzyme according to the present invention may be at least 1, atleast 2, at least 3, at least 4 or at least 5.
Suitably, the method according to the present invention may comprise testing the variant lipid acyltransferase for: (a) transferase activity from a galactolipid substrate, and (b) hydrolytic activity on a galactolipid substrate; and selecting a variant enzyme with an enhanced ratio of transferase activity from galactolipids compared with its hydrolytic activity on glycolipids, compared with the parent enzyme.
Suitably, the ratio of transferase activity on galactolipids compared to hydrolytic activity on galactolipids may be great than 1, at least 1.5, at least 2, at least 4 or at least
An assay for determining the transferase and hydrolytic activities from galactolipids and/or phospholipids is/are taught in Example 8 for example.
The term “enhanced activity towards galactolipids” means the enzyme has an enhanced (i.e. higher) transferase activity when the lipid acyl donor is a galactolipid compared with the parent enzyme (galactolipid transferase activity) and/or has an increased ratio of galactolipid transferase activity when compared with phospholipids transferase activity compared with the parent enzyme (GLt:PLt ratio) and/or has an increased ratio of galactolipid transferase activity when compared with galactolipid hydrolysis activity compared with the parent enzyme (GLt:GLh ratio).
Suitably, the variant enzyme compared with the parent enzyme may have an increased galactolipid transferase activity and either the same or less galactolipid hydrolytic activity. In other words, suitably the variant enzyme may have a higher galactolipid 1S transferase activity compared with its galactolipid hydrolytic activity compared with the parent enzyme. Suitably, the variant enzyme may preferentially transfer an acyl group from a galactolipid to an acyl acceptor rather than simply hydrolysing the galactolipid.
In one embodiment, the enzyme according to the present invention may have an increased transferase activity towards phospholipids (i.e an. increased phospholipid transferase activity) as compared with the parent enzyme. This increased phospholipid transferase activity may be independent of the enhanced activity towards galactolipids.
Suitably, however, the variant enzyme may have an increased galactolipid transferase activity and an increased phospholipid transferase activity.
In one embodiment the present invention provides a variant lipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif
GDSX, wherein X is one or more of the following amino acid residues L, A, V, L F,
Y,H Q T,N, M or S, wherein the variant has an enhanced activity towards phospholipids, preferably enhanced phospholipid transferase activity, compared with the parent enzyme and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
The term “modifying” as used herein means adding, substituting and/or deleting.
Preferably the term “modifying” means “substituting”.
For the avoidance of doubt, when an amino acid is substituted in the parent enzyme it is preferably substituted with an amino acid which is different from that originally found at that position in the parent enzyme thus to produce a variant enzyme. In other words, the term “substitution” is not intended to cover the replacement of an amino acid with the same amino acid.
Preferably, the parent enzyme is an enzyme which comprises the amino acid sequence shown as SEQ ID No. 2 and/or SEQ ID No. 28.
Preferably, the variant enzyme is an enzyme which comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4orset6orset7.
In one embodiment, preferably the variant enzyme comprises one or more amino acid modifications compared with the parent sequence at at least one of the amino acid residues defined in set 4.
Suitably, the variant enzyme comprises one or more of the following amino acid modifications compared with the parent enzyme:
S3E,A,G,K,M, Y,R,P,N, Tor G
E309Q, R or A, preferably Q or R -318Y, H, Sor Y, preferably Y.
Preferably, X of the GDSX motif is L. Thus, preferably the parent enzyme comprises the amino acid motif GDSL.
Preferably the method of producing a variant lipid acyltransferase enzyme further comprises one or more of the following steps: 1) structural homology mapping or 2) sequence homology alignment.
Suitably, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (ITVN.PDB) shown in
Figure 52; ii) selecting one or more amino acid residue within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53) (such as one or more of the amino acid residues defined in set 1 or set 2); and iii) modifying one or more amino acids selected in accordance with step (ii) in said parent sequence.
In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53).
Suitably, the structural homology mapping may comprise one or more of the following steps: 1) aligning a parent sequence with a structural model (1IVN.PDB) shown in
Figure 52; ii) selecting one or more amino acids within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53) (such as one or more of the amino acid residues defined in set 1 or set 2); jiiy determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and iv) modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence.
In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53).
Alternatively to, or in combination with, the structural homology mapping described above, the structureal homology mapping can be performed by selecting specific loop regions (LRs) or intervening regions (IVRs) derived from the pfam aligmment (Alignment 2, Figure 56) overlayed with the P10480 model and 1IVN. The loop regions (LRs) ot intervening regions (TVRs) are defined in the Table below:
P10480 amino acid positions (SEQ ID No 2)
Door CE mr
LT LA
Cor 025 me
Coo 00 er
Loop5 (LR5) 208-287
DL Cc A
In some embodiments of the present invention the variant acyltransferase enzyme not only comprises an amino acid modifications at one or more of the amino acids defined in any one of sets 1-4 and 6-7, but also comprises at least one amino acid modification in one or more of the above defined intervening regions (IVR 1-6) (preferably in one or more of the IVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above-defined loop regions (LR1-5) (preferably in one or more of LR1,LR2 or
LRS5, more preferably in LRS).
In one embodiment, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may comprise one or more amino acid modification which is not only defined by one or more of set 2,4,6and 7, but also is within one or more of the IVRs 1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LRS, more preferably within LRS).
Suitably, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 3.
Suitably, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 5.
Suitably, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may cornprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 6.
Suitably, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IR 1.
Suitably, the variant acyltransferase according to the present invention or obtained by a method according to the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within LR 2.
Likewise, in some embodiments of the present invention the variant acyltransferse enzyme not only comprises an amino acid modification at one or more amino acid residues which reside within a 10, preferably within 2 9, 8, 7, 6, 5, 4, or 3, A sphere centred on the central carbon atom of the glycerol molecule in the active site (see
Figure 53), but also comprises at least one amino acid modification in one or more of the above defined intervening regions (TVR1-6) (preferably in one or more of IVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above- defined loop regions (LR1-5) (preferably in one or more of LR1, LR2 or LRS, more preferably in LR5).
In one embodiment, preferably the amino acid modification is at one or more amino acid residues which reside within a 10A sphere and also within LRS.
Thus, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (1IVN.PDB) shown in
Figure 52; ii) selecting one or more amino acid residue within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see
Figure 53) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVR1-6) (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6); and/or selecting one or more amino acid residues within LR1-5 (preferably within LR1, LR2 or LRS, more preferably within LRS); and iii) modifying one or more amino acids selected in accordance with step (ii) in said parent sequence.
In one embodiment the amino acid residue selected may reside within a 9, preferably withina 8,7, 6, 5, 4, or 3 A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53).
Suitably, the structural homology mapping may comprise one or more of the following steps: i) aligning a parent sequence with a structural model (1IVN.PDB) shown in
Figure 52; : ii) selecting one or more amino acids within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVR1-6) (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6); and/or selecting one or more amino acid residues within LR1-5 (preferably within LR1, LR2 or LRS, more preferably within LRS5); iii) determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence.
Suitably, the one or more amino acids selected in the methods detailed above are not only within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53) (such as one or more of the amino acid residues defined in set 1 or set 2), but are also within one or more of the IVRs 1-6 (preferably within IVR 3, § or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LRS, more preferably within LRS).
In one embodiment, preferably the one or more amino acid modifications is/are within
LRS. When it is the case that the modification(s) is within LRS, the modification is not one which is defined in set 5. Suitably, the one or more amino acid modifications not only fall with the region defined by LR5, but also constitute an amino acid within one or more of set 2, set 4, set 6 or set 7.
Suitably, the sequence homology alignment may comprise one or more of the following steps:
i) selecting a first parent lipid acyltransferase; if) identifying a second related lipid acyltransferase having a desirable activity; iii) aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; iv) identifying amino acid residues that differ between the two sequences; and v) modifying one or more of the amino acid residues identified in accordance with step (iv) in said parent lipid acyltransferase.
Suitably, the sequence homology alignment may comprise one or more of the following steps: i) selecting a first parent lipid acyltransferase; if) identifying a second related lipid acyltransferase having a desirable activity; jiiy aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; iv) identifying amino acid residues that differ between the two sequences; v) determining if one or more amino acid residues selected in accordance with step (iv) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and vi) modifying one or more of the amino acid residues identified in accordance with step (iv) excluding conserved regions identified in accordance with step (v) in said parent sequence.
Suitably, said first parent lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQID No. 5,
SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ
ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID
No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45.
Suitably, said second related lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ
ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID
No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37,
SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45.
The variant enzyme must comprise at least one amino acid modification compared with the parent enzyme. In some embodiments, the variant enzyme may comprise at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10 amino acid modifications compared with the parent enzyme.
Suitably the methods according to the present invention may comprise a further step of formulating the variant enzyme into an enzyme composition and/or a foodstuff composition, such as a bread improving composition.
In order to align a GDSx polypeptide sequence (parent sequence) with SEQ ID No. 2 (P01480), sequence alignment such as pairwise alignment can be used (http://www.ebi.ac.uk/emboss/align/index. html). Thereby, the equivalent amino acids in alternative parental GDSx polypeptides, which correspond to one or more of the amino acids defined in set 2 or set 4 or set 6 or set 7 in respect of SEQ ID No. 2 can be determined and modified. As the skilled person will readily appreciate, when using the emboss pairwise alignment, standard settings usually suffice. Corresponding residues can be identified using “needle” in order to make an alignment that covers the whole length of both sequences. However, it is also possible to find the best region of similarity between two sequences, using “water”.
Alternatively, particularly in instances where parent GDSx polypeptides share low homology with SEQ ID No. 2, the corresponding amino acids in alternative parental
GDSx polypeptides which correspond to one or more of the amino acids defined in set 2, set 4, set 6 or set 7 in respect of SEQ ID No. 2 can be determined by structural alignment to the structural model of P10480, obtained by comparison of P10480 derived structural mode] with the structural coordinates of 1IIVN.PDB and 1DEO.PDB using the ‘Deep View Swiss-PDB viewer’ (obtained from www.expasy.org/spdbv/)
(Figure 53 and Example 1). Equivalent residues are identified as those overlapping or in closest proximity to the residues in the obtained structural model of P010480, as illustrated in the Table comparing Set 1 and Set 2 (see section entitled “Definition of
Sets” hereinabove). In this way other GDSX polypeptides can be compared against the 1TVN.PBD crystal co-ordinates, and equivalent residues to Set 1 determined.
Alternatively, particularly in instances where a parent GDSx polypeptide shares a low homology with SEQ ID No. 2, the equivalent amino acids in alternative parental GDSx polypeptides, which correspond to one or more of the amino acids defined in set 2 or set 4 or set 6 or set 7 in respect of SEQ ID No. 2 can be determined from an alignment obtained from the PFAM database (PFAM consensus) modified based on the structural alignment as shown in Alignment 1 (Figure 55). The modification based on the structural models may be necessary to slightly shift the alignment in order to ensure a best fit overlap. Alignment 1 (Figure 55) provides guidance in this regard.
The variant enzyme according to the present invention preferably does not comprise one or more of the amino acid modifications defined in set 5.
Suitably the variant enzyme may be prepared using site directed mutagenesis.
Alternatively, one can introduce mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify
PCR random mutagenesis kit from Clontech. EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those described in EP 0 866 796. Error prone PCR technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. W00206457 refers to molecular evolution of lipases.
A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as
Dnase I, and reassembling full nucleotide sequences coding for functiomal proteins (hereinafter referred to as “shuffling”). Alternatively one can use one or multiple non-
identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics.
Suitable methods for performing ‘shuffling’ can be found in EPO 752 008, EP1 138 763, EP1 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in US 6,180,406 and WO 01/34835.
Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded variant polypeptide by various means. ' As a non-limiting example, In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.
The following regions may preferably be selected for localised random mutagenesis and/or shuffling: IVR3, IVR 5, IVR 6, LR1, LR2, and/or LRS, most preferably LRS.
For the production of libraries of variants microbial eukaryotic or prokaryotic expression hosts may be used. In order to ensure uniform expression within a library of variants, low copy number, preferably single event chromosomal expression systems may be preferred. Expression systems with high transformation frequencies are also preferred, particularly for the expression of large variant libraries (>1000 colonies), such as those prepared using random mutagenesis and/or shuffling technologies.
Suitable methods for the use of a eukaryotic expression host, namely yeast, in the production of enzymes are described in EP1131416. Microbial eukaryotic expression hosts, such as yeast, may be preferred for the expression of variant libraries produced using a eukaryotic acyltransferase parent gene.
Suitable methods using Bacillus, i.e. Bacillus subtilis, as an expression host in the production of enzymes are described in W002/14490. Microbial prokaryotic expression hosts, such as Bacillus, may be preferred for the expression of variant libraries produced using a prokaryotic acyltransferase parent gene, for example the P10480 reference sequence (SEQ ID No 2).
Suitably, the variant lipid acyltransferase according to the present invention retains at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 97%, preferably at least 99% homology with the parent enzyme.
Suitable parent enzymes may include any enzyme with esterase or lipase activity.
Preferably, the parent enzyme aligns to the pfam00657 consensus sequence.
In a preferable embodiment a variant lipid acyltransferase enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks.
Enzymes, such as lipases with no or low lipid acyltransferase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the transferase activity, thereby producing a variant lipid acyltransferase enzyme with significant transferase activity suitable for use in the compositions and methods of the present invention.
Suitably, the lipid acyltransferase for use in the invention may be a variant with enhanced enzyme activity on polar lipids, preferably glycolipids, when compared to the parent enzyme. Preferably, such variants also have low or no activity on lyso polar lipids. The enhanced activity on polar lipids, preferably glycolipids may be the result of hydrolysis and/or transferase activity or a combination of both.
Variant lipid acyltransferases for use in the invention may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent enzyme.
Suitably the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides. Low activity on triglycerides is preferred in variant enzymes which are to be used for bakery applications, for treatment of egg or egg-based products and/or for degumming oils.
In one embodiment, suitably the variant enzyme may have a high activity on diglycerdies and no or low activity on triglycerides.
When referring to specific amino acid residues herein the sumbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID
No.2.
In one aspect preferably the variant enzyme comprises one or more of the following amino acid substitutions:
S3A,C,D,EF,GHLKLMN,PQR,T,V,W,or Y; and/or
L17A,C,D,E,F,G,H LK, M,N,P,QR,S, TV, W, or Y; and/or
S18A,C,D,E,F,H,LK,L,M,N,P,Q,R, T, W,or Y; and/or
K22A,C,D,E,F,G, H,LL,M,N,P,Q,R,S,T,V,W, or Y; and/or
M23A,C,D,E F,G,H,LK,L, N,P,Q, RS, T,V,W, or Y; and/or
Y30A,C,D,E,G,H,LK,L,M,N,P,QR,S,T, V, or W; and/or
G40A,C,D,E,F,H, LK,L,M,N,P,Q,R,S, T,V, W, or Y; and/or
N80OA,C,D,E,F,G, H,LK,L,M,P,QR,S,T,V,W, or Y; and/or
P81A,C,D,E F,G,H, LK,L,M,N,Q,R,S,T,V, W,or Y; and/or
K82A,C,D,E,F,G,H,LL,M,N,P,QR,S, T,V, W, or Y; and/or
N87A,C,D,E FG HILKULMPQRST,V,W,orY;and/or
N88A,C,D,E,F,G, H LK,L,MP,QR,S,T,V, W, or Y; and/or
Wi111A,C,D,EF, GH, LK,L,M,N,P,Q,R,S, T, V, Wor Y; and/or
V112A,C,D,E,F,G, H,LK,L,M,N,P,Q,R, S, T, W, or Y; and/or
Al14C,D,E,F,G,H,LK,L,M,N,P,Q,R,S, T, V, W, or Y; and/or
Y117A,C,D,E,F,G,H, LL K,L,M,N,P,Q,R, S, T, V, or W; and/or
L118A,C,D,E F,G, H, LK, M,N,P,Q,R,S, T, V, W, or Y; and/or
P156A,C,D,EF,G,H LK, L,M,N,QR,S,T,V, W, or Y; and/or
D157A,C,E,F,G,H,LK,L,M,P,Q,R,S,T, V, W, or Y; and/or
G159A,C,D,E, FH, K,L,M,N,P,Q,R,§, T, V, W, or Y; and/or
Q160A,C,D,E,F,G,H,LK,L,M,N,P,R, S, T,V, W, or Y; and/or
N161A,C,D,E,F,G,H,LK,L,MP,Q,R,S, T,V, W, or Y; and/or
P162A,C,D,E,F,G,H,LK,L, M,N,Q,R,S,T,V, W, or Y; and/or
S163A,C,D,E,F,G,H,LK,LLM,N,P,Q,R, T,V,W, or Y; and/or
Al64C,D,E,F,G,H,LK,L,M,N,P,Q,R,S8, T,V, W, or Y; and/or
R165A,C,D,E,F,G,H,LK,LM,N,P,Q,S, T,V, W, or Y; and/or
S166A,C,D,E,F,G,H,LK,L,M,N,P,Q,R, T, V, W, or Y; and/or
QI167A,C,D,E,F,G,H,LK,L,M,N,P,R,5,T,V, W, or Y; and/or
K168A,C,D,E,F,G,H,LL,M,N,P,Q,R,S, T, V, W, or Y; and/or
V169A,C,D,E,F,G,H,LK,L,M,N,P, QR, §, T, W, or Y; and/or
V170A,C,D,E,F,G, HL K,L,M,N,P,Q,R, 8, T, W, or Y; and/or
E171A,C,D,F,G,H,LK,L,M,N,P,Q,R, S, T, V, W, or Y; and/or
AIl72C,D,E,F,G,H,LK,L,M,N,P,Q,R,S, T, V, W, or Y; and/or
Y179A,C,D,E,F,G,H,L K,L,M,N,P,Q,R, S, T, V, or W; and/or
H180A,C,D,E,F,G,LK,L,M,P,Q,R,S, T, V, W, or Y; and/or
Ni181A,C,D,E,F,G,H,LK,L,M,P,Q,R,S, T, V, W, or Y; and/or
Q182A,C,D,E,F,G,H,LK,L,M,N,P,R,S5,T,V,W, or Y, preferably K; and/or
M209A,C,D,E F,G,H,LK,L,N,P,Q,R,S, T, V, W, or Y; and/or 1210A,C,D,E F,G,H,LK,M,N,P,Q,R,S, T, V, W, or Y; and/or
R211 A,C,D,E,F,G,H,LK,L,M,N,P,QR,S, T, V, W, or Y; and/or
N215A,C,D,E,F,G,H,K,L,M,N,P,Q,R,S, T, V, W, or Y; and/or
Y226A,C,D,E,G,H,LK,L,M,N,P,Q,R,S, T, V, or W; and/or
Y230A,C,D,E,G,H,LLK,L,M,N,P,Q,R,S, T, Vor W; and/or
K284A,C,D,E,F,G,H,LL,M,N,P,Q,R,S, T, V, W, or Y; and/or
M285A,C,D,E,F,G,H,LK,L,N,P,Q,R,S, T, V, W, or Y; and/or
Q289A,C,D,E,F,G,B, LK, L,M,N,P,R,S, T, V, W, or Y; and/or
V290A,C,D,E,F,G,H,LK,L, M,N, P,Q,R, S, T, W, or Y; and/or
E309A,C,D, F,G,H,K,L,M,N,P,Q,R,S, T, V, W, or Y; and/or
S310A,C,D,E,F,G,H, LK, LL M,N,P,QR, T,V,W,or Y.
In addition or alternatively thereto there may be one or more C-terminal extensions.
Preferably the additional C-terminal extension is comprised of one or more aliphatic amino acids, preferably a non-polar amino acid, more preferably of LL, V or G. Thus, the present invention further provides for a variant enzyme comprising one or more of the following C-terminal extensions: 318, 318L, 318V, 318G.
When it is the case that the residues in the parent backbone differ from those in
P10480 (SEQ ID No. 2), as determined by homology alignment and/or structural alignment to P10480 and/or 1IVN, it may be desirable to replace the residues which align to any one or more of the following amino acid residues in P10480 (SEQ ID No. 2): Ser3, Leul7, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87, Asn88, Trplll,
Vall12, Alal14, Tyr117, Leul18, Pro156, Gly159, GIn160, Asnl61, Prol62, Ser163,
Alal64, Argl65, Serl66, GIn167, Lys168, Val169, Val170, Glul71, Alal72, Tyrl79,
His180, Asn181, GIn182, Met209, Leu210, Arg211, Asn215, Lys284, Met285,
GIn289, Val290, Glu309 or Ser310, with the residue found in P10480 respectively.
The following wildtype residues of P10480 have been found to be preferable for retaining good activity, particularly good transferase activity from a galactolipid:, L17,
W111, R221, S3, G40, N88, K22, Y117, L118, N181, M209, M285, E309, M23. Thus preferably the variant enzyme comprises the amino acid residue found in P10480 at any one or more of these sites.
Variant enzymes which have an increased hydrolytic activity against a polar lipid may also have an increased transferase activity from a polar lipid.
Variant enzymes which have an increased hydrolytic activity against a phospholipid, such as phosphatidylcholine (PC) may also have an increased transferase activity from a phospholipid.
Variant enzymes which have an increased hydrolytic activity against a galactolipid, such as DGDG, may also have an increased transferase activity from a galactolipid.
Variants enzymes which have an increased transferase activity from a phospholipid, such as phosphatidylcholine (PC), may also have an increased hydrolytic activity against a phospholipid.
Variants enzymes which have an increased transferase activity from a galactolipid, such as DGDG, may also have an increased hydrolytic activity against a galactolipid.
Variants enzymes which have an increased transferase activity from a polar lipid may also have an increased hydrolytic activity against a polar lipid.
Suitably, one or more of the following sites may be involved in substrate binding:
Leul7; Alal14; Tyr179; His180; Asn181; Met209; Leu210; Arg211; Asn215; Lys284;
Met285; Gin289; Val290.
The variant enzyme in accordance with the present invention may have one or more of the following functionalities compared with the parent enzyme: } 1) an increased relative transferase activity against galactolipid (DG) compared to PC calculated as % Tpo/Tec (as illustrated in Example 8) 2) an increased absolute transferase activity against galactolipid (DG) (as illustrated in
Example 8) 3) an increased transferase activity using galactolipid as donor (Tbe) relative to the hydrolytic activity Hpg on galactolipid (DG) (as illustrated in Example 8) 4) an increased absolute transferase activity against PC (as illustrated in Example 8)
Wherein DG is galactolipid (e.g. DGDG) (and may be herein also referred to as GL) and PC is phospholipid (e.g. lecithin). Variants with an increased activity towards galactolipid include variants within categories 1), 2) and 3) above. Variants with an increased activity on galactolipids may also have an increased activity in phospholipids (as per category 4) above). 1. A modification to one or more of the following residues may result in a variant enzyme having an increased relative transferase activity against DG compared to PC calculated as % Tope/Tect 10-318, N215, L210, $310, E309, H180, N80, V112, Y30X (where X is selected from
ACD, E,GHLKLM, N, P,Q, R, S, T, V, or W), V290, Q289, K22, G40,
Y179, M209, L211, K22, P81, N87, Y117,N18l, Y230X (where X is selected from A,
C,D,E, GH LK LMNPQR,S,T,V, or W),Ql82.
Typically, one or more of the following substitutions may be preferred:
S3A,C,D,E,F,G,H,LK,L,M,N,P,Q,R, T, V, Wor Y, preferably M,R,N, G, T,
Q,P,Y,S,L,E, W, most preferably Q
K22A,E,C,F,G,H,LL,M,N,P,Q,R,S,T.V, Wor Y, preferably A,C,EorR
Y30A,C,D,H,K,M,N,P,QR,T,V,W,G LL, SM, A, RorE, preferably H, T,
W,N,D,C,QG,LL,S,M,A,RorE
G4OL,N,T,VorA
N8ON,R,D, A, C,E,F,G,H,LK,L,M,P,Q,S, T,V, Wor Y, preferably H, I, Y, C,
QMS, W,L,N,R,DorF
P8IA,C,D,E,F,GH,LK,L,M,N,Q,R,S,T,V, Wor, preferably L M, F, G, V,
Y,D,CorA
K82A,C,D,E,F,G,H, LL, M,N,P,Q,R,S,T,V,WorY, preferably H,K, Sor R
N87A,C,D,E,F,G,H,LK,L,M,P,Q,R,S,T,V,WorY, preferably, Y, M, T, Q,
S,W,F,VorP
N88A,C,D,E,FGHLKLMPQR,STYV, W or Y, preferably C, V, A or F v112C
Y117A,C,D,E,F,H,T,G LK, LLM,N,P,Q,R,S, Vor VW, preferably A, N, E, H,
T,LF,C,PorS
L118A,C,D,E F,G, H, LK, M,N,P,Q,R,S,T,V,W,orY, preferably F
V112A,D,E,F, GH, LK, LLM,N,P,Q,R,S, T, Wor Y, preferably I, M, F, Y, N,
ET, QHorP
Y179A,C,D,E,F,G, H,LK,L,M,N,P,Q,R, 5, T, V or W, preferably F, C,H, I, L,
M,P,VorW
H180K, Q, A, C,D,E,F,G, LLL, M,P,R,S,T,V,W, or Y, preferably M, F, C, K or
Q
Ni18lAorV
Q182A,C,D,EF,G, H,LK,M,N,P,Q,R, S, T,V, W, or Y, preferably K
M209L,K, M, A, C,D,E,F,G,H,LN,P,Q,R,S, T, V, W, or Y, preferably L, F, T,
D,C,H LK, MorP 1210G,L ,E,M,S, W,V,A,RN,D,Q.T,C,F,K,P or Y, preferably G, I, H, E,
M,S,W,V,A,RN,D,Q,T,YorF
R211G,Q,K,D,A,C,E,F, LLL M,N,P,R, 8, T, V, W or Y, preferably G, Q, K,
D,H,L,M,F,P,S,Y,N,C,Lor W
N215A,C,D,E,F,G,H,LK,L,M,N,P,Q,R,S,T,V, Wor Y, preferably LF, P, T,
W,Hor A
Y230A,C,D,E,G,H LK, L,M,N,P,QR,S,T,VorW, preferably I, T, G, D, R,
E, V, Mor S, most preferably I, D, R or E
Q289A,C,D,E,F,G,H, LK, LLM,N,P,R,S,T, V, W or Y, preferably F, W, H, I,
Y,L,D,C,K,V,E,G.R,N or P, more preferably R, T, D, K, Nor P .
V290A,C,D,E, H,F,G,LK,L,M,N,P,Q,R, 5, T, Wor Y;
E309S,Q,R,A,C,D,F,GHLKLMNPTV, Wor, preferably F, W, N, H,
LMS, QR AorY
S310A,P, T, §, MK, G,C,D,E,F, LL, N, Q,R,V, Wor Y, preferably F, Y,C,L,
KAPT,HMKorG 318A,C,D,E,F,G,LK,L,M,N,P,Q,R,T,V,W,Y,Hor 8
Preferably, one or more of the following modifications may result in a variant enzyme having an increased relative transferase activity against DG compared to PC calculated as % Tpo/ Tec
S3A,C,D,E,F,G,H,LK,LM,N,P,QR, TV, W or Y, preferably M, R,N, G, T,
Q,P,Y,S,L, E, W, most preferably Q
GAOL,N, T,Vor A
K82A,C,D,E,F,G, HLL, M,N,P,QR,S,T,V, W or Y, preferably H, K, Sor R
N88A,C,D,E,F,G H LK LM,P,QR,S,T,V, Wor Y, preferably C, V, Aor F
Y230A,C,D,E,G,H,LK,L,M,N,P,QR, S, T, V or W, preferably I, T, G, D, R,
E, V, M or S, most preferably D, R or E
Q289A,C,D,E, F,GH,LK,L,M,N,P,R,§5,T, V, W or Y, preferably F, W, H, I,
Y,L,D,C,K,V,E GorP, more preferably R, T, D,KorP
Modification of one or more of the following modifications results in a variant enzyme having an increased relative transferase activity against DG compared to PC calculated as % Tpa/Trc: -318Y,HorS
N215H
L210G,LH EMS, W,V,A,RN,D,QorT
S310A,P, T, HM, Kor G
E309S,Q,AorR
H180K, Tor Q
N8ON,R orD
V112C
Y30G,1,L, S,M, A, R or E, more preferably Y30M, AorR
V290R, E, Hor A
Q289R, T,D or N
K22E
G40L
Y179VorR
M209L, K orM
L211G,Q,KorD
Y230V
G40Q,LorV
N88W
N87RorD
For some embodiments the following substitutions may also be suitable:
K22A or C
P81G
N87M
Y117A,N,E,Hor T
N18lAorV
Y230I
V290H
N87R,D,EorM
Q182T
Preferably, the residues modified in order to increase the ratio of galactolipid transferase compared to phospholipid transferase activity are one or more of the following: -318, N215, L210, E309, H180, N80.
Typically, one or more of the following substitutions are preferred: -318 Y, H or S, most preferably Y
N2I15H 1L210D,QorT
E309QorR
H180K or Q
N8ON,RorD
2. A modification to one or more of the following residues may result in a variant having an increased absolute transferase activity against DG: -318, N215, L210, S310, E309, H180, N80, V112, Y30X (where X is selected from A,
C,D,E,G,H,LK,L,M,N,P,Q,R, S, T, V, or W), V290, Q 289, K22, G40, Y179,
M209, 1211, K22, P81, N87, Y117, N181, Y230X (where X is selected from A, C, D,
E,G, H LK LMN,PQRS,T,V,o W), V290, N87, Q182, 83, S310, K82,
A309.
In particular, one or more of the following modifications may result in a variant having an increased absolute transferase activity against DG: 318Y,H, S,A,C,D,E,F,G, LK, LLM,N,P,Q,R, T, Vor W, preferably Y, H, S or
I
N215A,C,D,E,F,G,H,LK,LLM,N,P,Q,R,S,T,V,WorY; preferably H, L F, P,
T,WorA, mostpreferably H, S,L,R, Y 1210G,L, H,E,M, 8S, W,V,A,RN,D,Q, T,C,F,K, Por, preferably D, Q, T, Y or F
S310A,P,T,H,M,K,G,C,D,E,F, LL, N,Q, RV, Wor. preferably F, Y,C,L,K orP,
E309S,Q,R,A,C,D,F,GH, LK, LLM,N,P,S,T,V,Wor Y; preferably S, Q, R,
F, W,N, H, I, Mor Y, most preferably S, Q, R,N,PorA
H180A, C,D,E,F,G,LK,QL,M,P,R,S, T, V, Wor Y; preferably K, Q, M, For C, most preferably T, K or Q
Ni8lAorV
N8ON,R,D,A,C EF GHLKLMP,QSTV, Wor, preferably H, I, Y, C,
QM, S,W,L,N,R, D or F, most preferably N,R, D,P, V, Aor G
V112A,C,D,E F,G, H,LK,L, ,N,P,Q,R,S,T, Wor Y; preferably , M, F, Y,
N,E, T,QHorP
Y30G,LL,S, AE C,D,H,K,M,N,P,Q RT, Vor VW, preferably H, T, W, N, D,
CorQ
V290A,C,D,E,F,G, H,LK,L,M,N,P,Q,R,S, T,WorY;
Q289A,C,D,E,F,G,H, LK, L,M,N,P,R,S,T, V, Wor ¥; preferably R, E, G, P,
NorR
K22A,C,E,F,G,H, LL, M,N,P,Q,R,S5,T,V,WorY, preferably C
Y179A,C,D,E,F,G, ,LLK,LLM,N,P,Q,R,§,T, Vor W; preferably F, C,H, I, L,
MM, P or W, more preferably E,R,N, V,K, 8
M209A,C,D,E,F,G,H,LLLK, M,N,P,Q,R,§,T, V, Wor Y; preferably R, N, Y,
EorV
R211A,C, EF, GH, LL, M,N,P,Q K,D,R,S,T,V, Wor, preferably H, I, M,
F,P,S,Y,N,C,L or W, most preferably R
S310C,D,E,F,LL,N,QRV,WorY. preferably F, Y,C,L,K or P
S3A,C,D,E,F,G,HLK,L,M,N,P,Q,R, T,V,W or Y, preferably M, R, N, A, G,
T, Q, P, Y or S most preferably Q or N
K82A,C,D,E,F,G, LLL M,N,P,QR, S,T,V, Wor Y, preferably H, K, S, E or
R
P8IA,C,D,E,F,GH LK,L,M,\N,QR,S,T.V,WorY; preferably LM, F, V, Y,
D,CorA
N87A,C,F,G,H,LK,L,M,P,Q,R,D,E,S, T, V, W or Y; preferably L, Gor A
Y117A,N,E,H, T,C,D,F,G, LK, L,M,P,Q,R, 8, Vor W; preferably LLF,C,Por
S
N87A,C,F,G,H,LK,L,P,Q,S,T,V,WorY; preferably I, ¥, T, Q,S,W,F,VorP
QI82A,C,D,E,F,G,H, LK, L,M,N,P,R, 8, T, V, W or Y, preferably D or K
Y230A,C,D,E,G,H, LK, L,M,N,P,Q,R, S,T, V or W, preferably W, HQL,P or C, most preferable T or G
D157A,C,E,F,G, H, LK, L,M,P,Q,R, S, T,V, Wor Y, preferably C
G4a0L
Y2261
Typically, one or more of the following substitutions are preferred: -318Y,HorS
N2I5H
L210G,L H,E,M,S,W,V,A,R,N,D,QorT
S310A,P, T,H,M,K or G
E309S,QorR
H180K or Q :
N8ON,RorD
V1i2C Y30G,LL,S,M,A,RorE, more preferably Y30M, A orR
V290R,E,Hor A
Q289R or N
K22E
G40L Y179V
M209L,K or M
L211G,Q,KorD
For some embodiments the following substitutions may also be suitable:
K22AorC
P81G
N87 M
Y117A,N,E,Hor T
N181AorV
Y230I
V290H
N87R,D,EorM
Q182T
Preferably, the residues modified in order to increase transferase activity from a galactolipid substrate (DGDG) are one or more of the following: -318, N215, L210,
E309, H180, N80.
Typically, one or more of the following substitutions are preferred: -318 Y, H or S, most preferably Y
N215H
L210D,QorT
E309Q or R
H180K or Q
N8ON, R or D 3. A modificiation at one or more of the following residues may result in a variant enzyme having an increased transferase activity Tp relative to the hydrolytic activity Hpg on DG:
Y230, S310, H180, Q289, G40, N88, Y179, N215, L210, N80, Y30X (where X is selected from A, C,D, E,G, H, LK, L, M,N, P,Q, R, §, T, V, or W), N87, M209,
R211, S18X (where X is specifically selected from A, C,D, E,F, , LK, L, M, N, P,
QR, T,WorY)
Preferably, one or more of the following modifications may result in a variant enzyme having an increased transferase activity Tpg relative to the hydrolytic activity Hpg on
DG:
Y230A,C,D,E, GH LK, L,M,N,P,QR,S, Tor W, preferably W, H, Q, L, P or
Cc
S310A,C,D,E,F, GH LK LMN,QR,T,V,WorY,preferablyF, Y,C,L,K orP
Y179A,C,D,E,F,G, H, LK,L,M,N,P,Q, S, T, V, or W, preferably F, C, H, I, L,
M,PorW
H180A,C,D,E,F,G, LK, L,M,P,Q,R,S,V, Wor Y, preferably M, F or C
Q289A,C,E,F,G,H,LK,L,M,N,P,R,S,V,WorY; preferably F, W,H, LY, L,
D,C,K,V,E,GorP
G40A,C,D,E,F,H,, K, M,N, P,R,S, T, Wor Y; preferably I, P, Wor Y
N88A,C,D,E,F,G,H,LLK,L,M,P,Q,R,S, T, V or Y; preferably I or H
N87A,C,E,F,G,H,LK,L,M,P,Q,S, T,V,WorY; preferably I, Y, T, Q, S, W, F,
VorP
Typically, one or more of the following substitutions are preferred (such variant enzymes may have a decreased hydrolytic activity (galactolipid and/or phospholipids) and/or an increased tranferase activity from galactolipid:
YI7T9E,R,NorQ
N215G
L210D,H,R,E, A, Q,P,N,K,G,R, T,W,L VorS
N80G
Y30L
N87G
Typically, one or more of the following substitutions are preferred (such variant enzymes may have a decreased hydrolytic activity (galactolipid and/or phospholipids) whilst retaining significant tranferase activity from galactolipid:
YI79E,R, N,Q
N2I5G
L210D,H, RE, A,Q,P,N,K,G,R, T,W,, Vand S
N80 G
Y30L
N87G
HI180LT
M209 Y
R211 D,Tand G
S18G,MandT
G40 Rand M
N88 W
N87C,D,R,E and G 4. Modification of one or more of the following residues may result in a variant enzyme having an increased absolute transferase activity against phospholipid:
S3, D157, $310, E309, Y179, N215, K22, Q289, M23, H180, M209, L210, R211, P81,
V112, N80, L82, N88; N87
Specific modifications which may provide a variant enzyme having an improved transferase andvity from a phospholipid may be selected from one or more of the following:
S3A,C,D,E,F,G,H LK, LLM,N,P,QRT,V,Wor Y; preferably N, E, K, R, A,
P or M, most preferably S3A
DI57A,C, EF, GH, LK, L,M,N,P,QR,S,T,V,WorY; preferably D157S, R,
E,N,G,T,V,Q,KorC
S310A,C,D,E, F,G,H,LK,L,M,N,P,Q,R, T,V, Wor; preferably S310T -318E
E309A,C,D,E, F,G,H,LK,LM,N,P,Q,R, T,V,WorY; preferably E309 R, E,
L,RorA
Y179A,C,D,E,F,G,H,LK,L,M,N,P,QR,S,T, Vor W; preferably Y179 D, T,
E,R,N, V,K, Q or S, more preferably E,R, N,V, KorQ
N215A, C,D,E, F,G,H,LK,L,M,P,Q,R, S, T, V, W or Y; preferably N215 §, L,
RorY
K22A,C,D,E,F,G,H,LL,MN,P,QR,S,T,V,Wor Y; preferably K22 E, R, C orA
Q289A,C,D,E,F,G,H,LK,L M,N,P,R,S,T,V,WorY; preferably Q289 R, E,
G,PorN
M23A,C,D,E,F,G,H,LK,LN,P,QR,S, T,V, Wor Y; preferably M23 K, Q, L,
G,TorS
H180A,C,D,E,F,G,LLK,L,M,P,Q,R,S, T,V, W or Y; preferably H180 Q,R or K
M209 A,C,D,E,F,G, H, LK,L,N,P,Q,R, S, T, V, W or Y; preferably M209 Q, S,
R,ANVY,E, VorL
L210A,C,D,E, F,G,H,LK,M,N,P,Q,R, S, T, V, W or Y; preferably L210 R, A,
V,S,T,LWorM
R211A,C,D,E,F,G,H,LK,L,M,N,P,Q,S, T, V, Wor Y; preferably R211T
P81A,C,D,E,F,G,H, LK, L, M,N, Q,R, S, T, V, W or Y; preferably P81G
V112A,C,D,E,F,G, H,LK,L,M,N,P,Q,R, S, T, W or Y; preferably V112C
N80A,C,D,E,F,G,H,LK,L,M,P,Q,R,S, T,V, Wor Y; preferably NO R, G, N,
D,P,T.E,V,AorG
L82A,C,D,E,F,G, H,, M,N,P,Q,R,S, T, V, W or Y; preferably L82N, Sor E
N88A,C,D,E,F,G,HLK LMP QR,S,T,V, Wor Y; preferably N88C
N87A,C,D,E,F,G, H,LK,L,M,P,Q,R,S, T, V, W or Y; preferably N§7M or G
Modification of one or more of the following residues results in a variant enzyme having an increased absolute transferase activity against phospholipid:
S3IN,R,A,G
M23K,Q,L,GT,S
HI80R
L82G
YIT9E,R,N,V,KorQ
E309R,S,LorA 5. Residues the modification of which results in an increased transferase activity from a galactolipid substrate (DGDG) and an increase in ratio of galactolipid transferase compared to phospholipid transferase activity include one or more of: - 318, N215, 1.210, S310, E309, H180, N80, V112, Y30X (where X is selected from A,
C,D,E,G,H,LK,L, M,N,P,Q,R,S, T, V, or W), V290, Q 289, K22, G40, Y179,
M209, 1211, K22, P81, N87, Y117, N181, Y230X (where X is selected from A, C, D,
E,GHLKLMN,P,QR,S,T,V,orW),QI82.
Typically, one or more of the following substitutions are preferred: -318Y,HorS
N215H
L210G,L H,E,M,S,W, V,A,R,N,D,Qor T
S310A,P,T,H,M,KorG
E309S, A, QorR
H180K or Q
N8ON, R or D
Vii2C
Y30G, LL, S,M, A, R or E, more preferably Y30M, A orR
V290R,E,Hor A
Q289RorN
K22E
G40L
Y179V
M209L,K or M
L211G,Q,KorD
For some embodiments the following substitutions may also be suitable:
K22A or C
P81G
N87M
Y117A,N,E,Hor T
Ni18lAorV
Y230I
V290H
N87R,D,EorM
Q182T
Preferably, the residues modified in order to increase transferase activity from a galactolipid substrate (DGDG) and/or increase the ratio of galactolipid transferase compared to phospholipid transferase activity are one or more of the following: -318,
N215, L210, E309, H180, N80.
Typically, one or more of the following substitutions are preferred: -318Y,HorS, most preferably Y
N215H
L210D,Qor T
E309QorR
H180K or Q
N8ON,Ror D 6. The following wildtype residues of P10480 have been found to be preferable for retaining good activity, particularly good transferase activity from a galactolipid:
Ww111,R211, N181, 83,L17, G40, N88, Y117, L118, N181, X22, M209, M285, M23
Preferably, these residues are retained in the variant enzyme.
When making variant GDSx acyl-transferases for increased activity transferase from galactolipid substrates, where the parent enzyme has a residue corresponding to residues of the P10480 sequence at positions W111, R211, N181, S3, L17, G40, N88,
Y117, L118, N181, K22, M209, M285, M23 other than the residue found in P10480 the variant may preferably contain a substitution at the corresponding position to include the amino acid residue found in the P10480 sequence.
L17 is preferably a hydrophobic amino acid residue 7. The following combinations may have an increased transferase activity from a galactolipid substrate (DGDG) and/or an increase in ratio of galactolipid transferase activity compared to phospholipid transferase activity
N215H & -318Y
N215H & L210D,Q,or T -318Y & L.210,D,Q, or T
N215H & -318Y & L210D, Q,or T
The above combinations may optionally also include a C-terminal amino acid addition, such as -318Y, Hor S, or preferably -318Y.
The above combinations may optionally also include the following modification:
Suitably one or more of the following combinations may have an increased transferase activity from a galactolipid substrate (DGDG) and/or an increase in ratio of galactolipid transferase activity compared to phospholipid transferase activity:
E309A, QorR.
N215H & -318Y, H, or S, preferably Y. 1210D, Qor T & -318Y, H, or S, preferably Y.
N215H & E309A,QorR
L210D, Qor T & E309A, QorR -318Y & E309A,QorR
The above combinations may optionally also include a substitution at position Q182, preferably Q182K.
The following combinations may have an increased transferase activity from a galactolipid substrate (DGDG) and/or an increase in ratio of galactolipid transferase activity compared to phospholipid transferase activity, and/or an increase in ratio of galactolipid transferase compared to hydrolytic activity:
N215H & N80G -318Y & N80G
L210D or Q & N80G
N215H & N88N -318Y & N88N
L210D or Q & N88N
N215H & Y30L -318Y & Y30L
L210DorQ & Y30L
N215H & N87G -318Y & N87G
L210D or Q &N87G
N215H & Y179E,R, Nor Q 318Y& Y179E,R,NorQ
L210DorQ & YI79E,R, Nor Q
As noted above, when referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 2.
For the avoidance of doubt, when a particular amino acid is taught at a specific site, for instance 1.118 for instance, this refers to the specific amino acid at residue number 118 in SEQ ID No. 2. However, the amino acid residue at site 118 in a different parent enzyme may be different from leucine.
Thus, when taught to substitute an amino acid at residue 118, although reference may be made to L118 it would be readily understood by the skilled person that when the parent enzyme is other than that shown in SEQ ID No. 2, the amino acid being substituted may not be leucine. It is, therefore, possible that when substituting an amino acid sequence in a parent enzyme which is not the enzyme having the amino acid sequence shown as SEQ ID No. 2, the new (substituting) amino acid may be the same as that taught in SEQ ID No. 2. This may be the case, for instance, where the amino acid at say residue 118 is not leucine and is, therefore different from the amino acid at residue 118 in SEQ ID No. 2. In other words, at residue 118 for example, if the parent enzyme has at that position an amino acid other than leucine, this amino acid may be substituted with leucine in accordance with the present invention.
The term “lipid acyltransferase” as used herein means an enzyme which has acyltransferase activity (generally classified as E.C. 2.3.1.x in accordance with the
Enzyme Nomenclature Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology), whereby the enzyme is capable of transferring an acyl group from a lipid to one or more acceptor substrates,
such as one or more of the following: a sterol; a stanol; a carbohydrate; a protein; a protein subunit; glycerol.
Preferably the lipid acyltransferase is capable of transferring an acyl group from a lipid to at least a sterol and/or a stanol, for example to cholesterol.
Preferably, the lipid acyltransferase variant according to the present invention and/or for use in the methods and/or uses of the present invention is capable of transferring an acyl group from a lipid (as defined herein) to one or more of the following acyl acceptor substrates: a sterol, a stanol, a carbohydrate, a protein or subunits thereof, or a : glycerol.
For some aspects the “acyl acceptor” according to the present invention may be any compound comprising a hydroxy group (-OH), such as for example, polyvalent alcohols, including glycerol; sterol; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed protein) for example; and mixtures and derivatives thereof. Preferably, the “acyl acceptor” according to the present invention is not water.
In one embodiment, the acyl acceptor is preferably not a monoglyceride and/or a diglyceride. Co :
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to a sterol and/or a stanol.
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to a carbohydrate.
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to a protein or a subunit thereof. Suitably the protein subunit may be one or more of the following: an amino acid, a protein hydrolysate, a peptide, a dipeptide, an oligopeptide, a polypeptide.
Suitably in the protein or protein subunit the acyl acceptor may be one or more of the following constituents of the protein or protein subunit: a serine, a threonine, a tyrosine, or a cysteine.
When the protein subunit is an amino acid, suitably the amino acid may be any suitable amino acid. Suitably the amino acid may be one or more of a serine, a threonine, a tyrosine, or a cysteine for example.
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to glycerol.
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to a hydroxy acid.
In one aspect, preferably the variant enzyme is capable of transferring an acyl group from a lipid to a polyvalent alcohol.
In one aspect, the variant lipid acyltransferase may, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally be able to transfer the acyl group from a lipid to one or more of the following: a carbohydrate, a protein, a protein subunit, glycerol.
Preferably, the lipid substrate upon which the variant lipid acyltransferase according to the present invention acts is one or more of the following lipids: a phospholipid, such as a lecithin, e.g. phosphatidylcholine, a triacylglyceride, a cardiolipin, a diglyceride, or a glycolipid, such as digalactosyldiglyceride (DGDG) or monogalactosyldiglyceride (MGDG) for example. More preferably, the variant enzyme according to the present invention acts on one or both of DGDG and MGDG. Preferably, the variant enzyme according to the present invention has no (or has only limited) activity on digalactosylmonoglyceride (DGMG) and monogalactosylmonoglyceride (MGMG).
Thus preferably the lipid substrate is not one or both of DGMG or MGMG. This lipid substrate may be referred to herein as the “lipid acyl donor”. The term lecithin as used herein encompasses phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol.
The term “galactolipid” as used herein means one or more of DGDG or DGMG.
The term “phospholipid” as used herein. means lecithin, including phospbatidylcholine. « The term “polar lipid” as used herein means a phospholipids and/or a galactolipid, preferably a phospholipids and a galactolipid.
For some aspects, preferably the lipid substrate upon which the variant lipid acyltransferase acts is a phospholipid, such as lecithin, for example phosphatidylcholine.
For some aspects, preferably the lipid substrate is a glycolipid, such as DGDG or
MGDG for example.
Preferably the lipid substrate is a food lipid, that is to say a lipid component of a foodstuff.
For some aspects, preferably the variant lipid acyltransferase according to the present invention is incapable, or substantially incapable, of acting on a triglyceride and/or a 1- monoglyceride and/or 2-monoglyceride.
Suitably, the lipid substrate or lipid acyl donor may be one or more lipids present in one or more of the following substrates: fats, including lard, tallow and butter fat; oils including oils extracted from or derived from palm oil, sunflower oil, soya bean oil, safflower oil, cotton seed oil, ground nut oil, corn oil, olive oil, peanut oil, coconut oil, and rape seed oil. Lecithin from soya, rape seed or egg yolk is also a suitable lipid substrate. The lipid substrate may be an oat lipid or other plant based material containing galactolipids.
In one aspect the lipid acyl donor is preferably lecithin (such as phosphatidylcholine) ineggyolk
For some aspects of the present invention, the lipid may be selected from lipids having a fatty acid chain length of from 8 to 22 carbons.
For some aspects of the present invention, the lipid may be selected from lipids having a fatty acid chain length of from 16 to 22 carbons, more preferably of from 16 to 20 carbons.
For some aspects of the present invention, the lipid may be selected from lipids having a fatty acid chain length of no greater than 14 carbons, suitably from lipids having a fatty acid chain length of from 4 to 14 carbons, suitably 4 to 10 carbons, suitably 4 to 8 carbons.
Suitably, the variant lipid acyltransferase according to the present invention may exhibit one or more of the following lipase activities: glycolipase activity (E.C. 3.1.1.26), triacylglycerol lipase activity (E.C. 3.1.1.3), phospholipase A2 activity (E.C. 3.1.1.4) or phospholipase Al activity (E.C. 3.1.1.32). The term “glycolipase activity” as used herein encompasses “galactolipase activity”.
Suitably, the variant lipid acyltransferase according to the present invention may have at least one or more of the following activities: glycolipase activity (E.C. 3.1.1.26) and/or phospholipase Al activity (E.C. 3.1.1.32) and/or phospholipase A2 activity (E.C.3.1.14).
For some aspects, the variant lipid acyltransferase according to the present invention may have at least glycolipase activity (B.C. 3.1.1.26).
Suitably, for some aspects the variant lipid acyltransferase according to the present invention may be capable of transferring an acyl group from a glycolipid and/or a phospholipid to one or more of the following acceptor substrates: a sterol, a stanol, a carbohydrate, a protein, glycerol.
For some aspects, preferably the variant lipid acyltransferase according to the present invention is capable of transferring an acyl group from a glycolipid and/or a phospholipid to a sterol and/or a stanol to form at least a sterol ester and/or a stanol ester.
For some aspects, preferably the variant lipid acyltransferase according to the present invention is capable of transferring an acyl group from a glycolipid and/or a phospholipid to a carbohydrate to form at least a carbohydrate ester.
For some aspects, preferably the variant lipid acyltransferase according to the present invention is capable of transferring an acyl group from a glycolipid and/or a phospholipid to a protein to form at least protein ester (or a protein fatty acid condensate).
For some aspects, preferably the variant lipid acyltransferase according to the present invention is capable of transferring an acyl group from a glycolipid and/or a phospholipid to glycerol to form at least a diglyceride and/or a monoglyceride.
For some aspects, preferably the variant lipid acyltransferase according to the present invention does not exhibit triacylglycerol lipase activity (E.C. 3.1.1.3).
In some aspects, the variant lipid acyltransferase may be capable of transferring an acyl group from a lipid to a sterol and/or a stanol. Thus, in one embodiment the “acyl acceptor” according to the present invention may be either a sterol or a stanol or a combination of both a sterol and a stanol.
A
In one embodiment suitably the sterol and/or stanol may comprise one or more of the following structural features: i) a 3-beta hydroxy group or a 3-alpha hydroxy group; and/or ii) A:B rings in the cis position or A:B rings in the trans position or Cs-Cs is unsaturated.
Suitable sterol acyl acceptors include cholesterol and phytosterols, for example alpha- sitosterol, beta-sitosterol, stigmasterol, ergosterol, campesterol, 5,6-dihydrosterol, brassicasterol, alpha-spinasterol, beta-spinasterol, gamma-spinasterol, deltaspinasterol, fucosterol, dimosterol, ascosterol, serebisterol, episterol, anasterol, hyposterol, chondrillasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sterol glycosides, and other natural or synthetic isomeric forms and derivatives.
In one aspect of the present invention suitably more than one sterol and/or stanol may act as the acyl acceptor, suitably more than two sterols and/or stanols may act as the acyl acceptor. In other words, in one aspect of the present invention, suitably more than one sterol ester and/or stanol ester may be produced. Suitably, when cholesterol is the acyl acceptor one or more further sterols or one or more stanols may also act as the acyl acceptor. Thus, in one aspect, the present invention provides a method for the in situ production of both a cholesterol ester and at least one sterol or stanol ester in combination. In other words, the lipid acyltransferase for some aspects of the present invention may transfer an acyl group from a lipid to both cholesterol and at least one further sterol and/or at least one stanol.
In one aspect, preferably the sterol acyl acceptor is one or more of the following: alpha-sitosterol, beta-sitosterol, stigmasterol, ergosterol and campesterol.
In one aspect, preferably the sterol acyl acceptor is cholesterol. When it is the case that cholesterol is the acyl acceptor for the variant lipid acyltransferase, the amount of free cholesterol in the foodstuff is reduced as compared with the foodstuff prior to exposure to the variant lipid acyltransferase and/or as compared with an equivalent foodstuff which has not been treated with the variant lipid acyltransferase.
Suitable stanol acyl acceptors include phytostanols, for example beta-sitostanol or ss- sitostanol.
In one aspect, preferably the sterol and/or stanol acyl acceptor is a sterol and/or a stanol other than cholesterol.
In some aspects, the foodstuff prepared in accordance with the present invention may be used to reduce blood serum cholesterol and/or to reduce low density lipoprotein.
Blood serum cholesterol and low density lipoproteins have both been associated with certain diseases in humans, such as atherosclerosis and/or heart disease for example.
Thus, it is envisaged that the foodstuffs prepared in accordance with the present invention may be used to reduce the risk of such diseases.
Thus, in one aspect the present invention provides the use of a foodstuff according to the present invention for use in the treatment and/or prevention of atherosclerosis and/or heart disease. Thus is one aspect the foodstuff may be considered as a neutraceutical.
In a further aspect, the present invention provides a medicament comprising a foodstuff according to the present invention.
In a further aspect, the present invention provides a method of treating and/or preventing a disease in a human or animal patient which method comprises administering to the patient an effective amount of a foodstuff according to the present invention.
Suitably, the sterol and/or the stanol “acyl acceptor” may be found naturally within the foodstuff, Alternatively, the sterol and/or the stanol may be added to the foodstuff.
When it is the case that a sterol and/or a stanol is added to the foodstuff, the sterol and/or stanol may be added before, simultaneously with, and/or after the addition of the lipid acyltransferase according to the present invention. Suitably, the present invention may encompass the addition of exogenous sterols/stanols, particularly phytosterols/phytostanols, to the foodstuff prior to or simultaneously with the addition of the variant enzyme according to the present invention.
For some aspects, one or more sterols present in the foodstuff may be converted to one or more stanols prior to or at the same time as the variant lipid acyltransferase is added according to the present invention. Any suitable method for converting sterols to stanols may be employed. For example, the conversion may be carried out by chemical hydrogenation for example. The conversion may be conducted prior to the addition of the variant lipid acyltransferase in accordance with the present invention or simultaneously with the addition of the variant lipid acyltransferase in accordance with the present invention. Suitably enzymes for the conversion of sterol to stanols are taught in WO00/061771.
Suitably the present invention may be employed to produce phytostanol esters in situ in a foodstuff. Phytostanol esters have increased solubility through lipid membranes, bioavailability and enhanced health benefits (see for example W092/99640).
In some embodiments of the present invention the stanol ester and/or the sterol ester may be a flavouring and/or a texturiser. In which instances, the present invention encompasses the in situ production of flavourings and/or texturisers.
In one embodiment, the present invention provides a method of producing a plant sterol ester and/or stanol ester and lysolecithin in an edible oil (such as a plant oil, such as soya bean oil for instance) without the formation of free fatty acids by treatment of the oil with a variant enzyme according to the present invention. In such instances the lysolecithin so produced may be removed using a degumming process. Any degumming process may be used, such as one or more of the known degumming processes. Any free fatty acids can be removed by deodorizing if necessary. Notably, any stanol/sterol ester produced in the oil is not removed by the deodorizing process.
Thus, the edible oil produced comprises sterol esters and/or stanol esters which may have beneficial nutritional and/or nutriceutical effects, such as lowering blood cholesterol levels.
Suitable oils in which this method could be carried out are those comprising inter alia lecithin and a sterol/stanol. Suitably, the oil is a crude oil when treated. Suitably, the edible oil may be one or more of the following: corn germ oil, cotton seed oil, linseed oil, palm oil, peanut oil, rapeseed oil, sesame oil, soybean oil, sunflower oil and wheat germ oil.
For some aspects of the present invention, the variant lipid acyltransferase according to the present invention may utilise a carbohydrate as the acyl acceptor. The carbohydrate acyl acceptor may be one or more of the following: a monosaccharide, a disaccharide, an oligosaccharide or a polysaccharide. Preferably, the carbohydrate is one or more of the following: glucose, fructose, anhydrofructose, maltose, lactose, sucrose, galactose, xylose, xylooligosacharides, arabinose, maltooligosaccharides, tagatose, microthecin, ascopyrone P, ascopyrone T, cortalcerone.
Suitably, the carbohydrate “acyl acceptor” may be found naturally within the foodstuff. Alternatively, the carbohydrate may be added to the foodstuff. When it is the case that the carbohydrate is added to the foodstuff, the carbohydrate may be added before, simultaneously with, and/or after the addition of the variant lipid acyltransferase according to the present invention.
Carbohydrate esters can function as valuable emulsifiers in foodstuffs. Thus, when it is the case that the enzyme functions to transfer the acyl group to a sugar, the invention encompasses the production of a second in situ emulsifier in the foodstuff.
In some embodiments, the variant lipid acyltransferase may utilise both a sterol and/or stanol and a carbohydrate as an acyl acceptor.
The utilisation of a variant lipid acyltransferase which can transfer the acyl group to a carbohydrate as well as to a sterol and/or a stanol is particularly advantageous for foodstuffs comprising eggs. In particular, the presence of sugars, in particular glucose, in eggs and egg products is often seen as disadvantageous. Egg yolk may comprise up to 1% glucose. Typically, egg or egg based products may be treated with glucose oxidase to remove some or all of this glucose. However, in accordance with. the present invention this unwanted sugar can be readily removed by “esterifying’> the sugar to form a sugar ester.
For some aspects of the present invention, the variant lipid acyltransferase according to the present invention may utilise a protein as the acyl acceptor. Suitably, the protein may be one or more of the proteins found in a food product, for example in a dairy product and/or a meat product. By way of example only, suitable proteins may be those found in curd or whey, such as lactoglobulin. Other suitable proteins include ovalbumin from egg, gliadin, glutenin, puroindoline, lipid transfer proteins from grains, and myosin from meat.
Preferably, the parent lipid acyltransferase enzyme according to the present invention may be characterised using the following criteria: @) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor to form a new ester; and (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein
X is one or more of the following amino acid residues L, A, V, LL F, Y,
H,Q,T,N,MorS.
Preferably, X of the GDSX motif is L. Thus, preferably the enzyme according to the present invention comprises the amino acid sequence motif GDSL.
The GDSX motif is comprised of four conserved amino acids. Preferably, the serine within the motif is a catalytic serine of the lipid acyltransferase enzyme. Suitably, the serine of the GDSX motif may be in a position corresponding to Ser-16 in Aeromonas hydrophila lipolytic enzyme taught in Brumlik & Buckley (Journal of Bacteriology
Apr. 1996, Vol. 178, No. 7, p 2060-2064).
To determine if a protein has the GDSX motif according to the present invention, the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database.
Pfam is a database of protein domain families. Pfam contains curated multiple sequence alignments for each family as well as profile hidden Markov models (profile
HMMs) for identifying these domains in new sequences. An introduction to Pfam can be found in Bateman A ef al. (2002) Nucleic Acids Res. 30; 276-280. Hidden Markov models are used in a number of databases that aim at classifying proteins, for review see Bateman A and Haft DH (2002) Brief Bioinform 3; 236-245. http://www.ncbi.nim nih gov/entrez/query.fcgi?cmd=Retrieve&db=PubMedé& list uids =12230032&dopt=Abstract =11752314&dopt=Abstract
For a detailed explanation of hidden Markov models and how they are applied in the
Pfam database see Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge University
Press, ISBN 0-521-62041-4. The Hammer software package can be obtained from
Washington University, St Louis, USA.
Alternatively, the GDSX motif can be identified using the Hammer software package, the instructions are provided in Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge
University Press, ISBN 0-521-62041-4 and the references therein, and the HMMER2 profile provided within this specification.
The PFAM database can be accessed, for example, through several servers which are currently located at the following websites. http://www.sanger.ac.uk/Software/Pfam/index.shtml http:/pfam.wustl.edu/ http://pfam jouy.inra.fr/ http://pfam.cgb ki.se/
The database offers a search facility where one can enter a protein sequence. Using the default parameters of the database the protein sequence will then be analysed for the presence of Pfam domains. The GDSX domain is an established domain in the database and as such its presence in ‘any query sequence will be recognised. The database will return the alignment of the Pfam00657 consensus sequence to the query sequence.
A multiple alignment, including Aeromonas salmonicida or Aeromonas hydrophila can be obtained by: a) manual obtain an alignment of the protein of interest with the Pfam00657 consensus sequence and obtain an alignment of P10480 with the Pfam00657 consensus sequence following the procedure described above; or b) through the database
After identification of the Pfam00657 consensus sequence the database offers the option to show an alignment of the query sequence to the seed alignment of the Pfam00657 consensus sequence. P10480 is part of this seed alignment and is indicated by GCAT_AERHY. Both the query sequence and P10480 will be . displayed in the same window.
The Aeromonas hydrophila reference sequence:
The residues of Aeromonas hydrophila GDSX lipase are numbered in the NCBI file
P10480, the numbers in this text refer to the numbers given in that file which in the present invention is used to determine specific amino acids residues which, in a preferred embodiment are present in the lipid acyltransferase enzymes of the invention.
The Pfam alignment was performed (Figure 33 and Figure 34):
The following conserved residues can be recognised and in a preferable embodiment may be present in the variant enzymes for use in the compositions and methods of the invention;
Block 1 —- GDSX block hid hid hid hid Gly Asp Ser hid 28 29 30 31 32 33 34 35
Block 2 — GANDY block hid Gly hid Asn Asp hid 130 131 132 133 134 135
Block 3 — HPT block
His 309
Where 'hid' means a hydrophobic residue selected from Met, Ile, Leu, Val, Ala, Gly,
Cys, His, Lys, Trp, Tyr, Phe.
Preferably the parent and/or variant lipid acyltransferase enzyme for use in the compositions/methods of the invention can be aligned using the Pfam00657 consensus sequence.
Preferably, a positive match with the hidden markov model profile (HMM profile) of the pfam00657 domain family indicates the presence of the GDSL or GDSX domain according to the present invention.
Preferably when aligned with the Pfam00657 consensus sequence the parent and/or variant lipid acyltransferase for use in the compositions/methods of the invention have at least one, preferably more than one, preferably more than two, of the following, a
GDSx block, a GANDY block, a HPT block. Suitably, the parent and/or variant lipid acyltransferase may have a GDSx block and a GANDY block. Alternatively, the parent and/or variant enzyme may have a GDSx block and a HPT block. Preferably the parent and/or variant enzyme comprises at least a GDSx block.
Preferably, when aligned with the Pfam00657 consensus sequence the parent and/or variant enzyme for use in the compositions/methods of the invention have at least one, preferably more than one, preferably more than two, preferably more than three, preferably more than four, preferably more than five, preferably more than six, preferably more than seven, preferably more than eight, preferably more than nine, preferably more than ten, preferably more than eleven, preferably more than twelve, preferably more than thirteen, preferably more than fourteen, of the following amino acid residues when compared to the reference A. hydrophilia polypeptide sequence, namely SEQ ID No. 26: 28hid, 29hid, 30hid, 31hid, 32gly, 33Asp, 34Ser, 35hid, 130hid, 131Gly, 132Hid, 133Asn, 134Asp, 135hid, 309His
The pfam00657 GDSX domain is a unique identifier which distinguishes proteins possessing this domain from other enzymes.
The pfam00657 consensus sequence is presented in Figure 1 as SEQ ID No. 1. This is derived from the identification of the pfam family 00657, database version 6, which may also be referred to as pfam00657.6 herein.
The consensus sequence may be updated by using further releases of the pfam database.
For example, Figures 33 and 34 show the pfam alignment of family 00657, from database version 11, which may also be referred to as pfam00657.11 herein.
The presence of the GDSx, GANDY and HPT blocks are found in the pfam family 00657 from both releases of the database. Future releases of the pfam database can be used to identify the pfam family 00657.
Preferably, the parent lipid acyltransferase enzyme according to the present invention may be characterised using the following criteria: @) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to acyl acceptor to form a new ester; (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein
X is one or more of the following amino acid residues L, A, V,L F, Y,
H,QT,N,MorS,; (iii) the enzyme comprises His-309 or comprises a histidine residue at a position corresponding to His-309 in the Aeromonas hydrophila lipolytic enzyme shown in Figure 2 (SEQ ID No. 2 or SEQ ID No. 26).
Preferably, the amino acid residue of the GDSX motif is L.
In SEQ ID No. 26 the first 18 amino acid residues form a signal sequence. His-309 of the full length sequence, that is the protein including the signal sequence, equates to
His-291 of the mature part of the protein, ie. the sequence without the signal sequence.
Preferably, the parent lipid acyltransferase enzyme according to the present invention comprises the following catalytic triad: Ser-16, Asp-116 and His-291 or comprises a serine residue, an aspartic acid residue and a histidine residue, respectively, at positions corresponding to Ser-16, Asp-116 and His-291 in the Aeromonas hydrophila lipolytic enzyme shown in Figure 2 (SEQ ID No. 2) or at positions corresponding to Ser-34, Asp-134 and His-309 of the full length sequence shown in Figure 28 (SEQ ID
No. 26). As stated above, in the sequence shown in SEQ ID No. 26 the first 18 amino acid residues form a signal sequence. Ser-34, Asp-134 and His-309 of the full length sequence, that is the protein including the signal sequence, equate to Ser-16, Asp-116 and His-291 of the mature part of the protein, i.e. the sequence without the signal sequence. In the pfam00657 consensus sequence, as given in Figure 1 (SEQ ID No. 1) the active site residues correspond to Ser-7, Asp-157 and His-348.
Preferably, the parent lipid acyltransferase enzyme according to the present invention may be characterised using the following criteria: i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a first lipid acyl donor is transferred to an acyl acceptor to form a new ester; and (ii) the enzyme comprises at least Gly-14, Asp-15, Ser-16, Asp-116 and
His-191 at positions corresponding to Aeromonas hydrophila enzyme in
Figure 2 (SEQ ID No. 2) which is equivalent to positions Gly-32, Asp- 33, Ser-34, Asp-134 and His-309, respectively, in Figure 28 (SEQ ID
No. 26).
Suitably, the parent lipid acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from organisms from one or more of the following genera: Aeromonas, Corynebacterium, Novosphingobium, Termobifida,
Streptomyces, Saccharomyces, Lactococcus, Mycobacterium, Streptococcus,
Lactobacillus, Desulfitobacterium, Bacillus, Campylobacter, Vibrionaceae, Xylella,
Sulfolobus, Aspergillus, Schizosaccharomyces, Listeria, Neisseria, Mesorhizobium,
Ralstonia, Xanthomonas and Candida. :
Suitably, the parent lipid acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from one or more of the following organisms:
Aeromonas hydrophila, Aeromonas salmonicida, Streptomyces coelicolor,
Streptomyces rimosus, Mycobacterium, Streptococcus pyogenes, Lactococcus lactis,
Streptococcus pyogenes, Streptococcus thermophilus, Lactobacillus helveticus,
Desulfitobacterium dehalogenans, Bacillus sp, Campylobacter jejuni, Vibrionaceae,
Xylella fastidiosa, Sulfolobus solfataricus, Saccharomyces cerevisiae, Aspergillus terreus, Schizosaccharomyces pombe, Listeria innocua, Listeria monocytogenes,
Neisseria meningitidis, Mesorhizobium loti, Ralstonia solanacearum, Xanthomonas campestris, Xanthomonas axonopodis, Corynebacterium efficens, Novosphingobium aromaticivorans, Termobifida fusca and Candida parapsilosis.
In one aspect, preferably the parent lipid acyltransferase enzyme according to the present invention is obtainable, preferably obtained, from one or more of Aeromonas hydrophila or Aeromonas salmonicida.
In one aspect, the parent lipid acyltransferase according to the present invention may be a lecithin:cholesterol acyltransferases (LCAT) or variant thereof (for example a variant made by molecular evolution)
Suitable LCATs are known in the art and may be obtainable from one or more of the following organisms for example: mammals, rat, mice, chickens, Drosophila melanogaster, plants, including Arabidopsis and Oryza sativa, nematodes, fungi and yeast.
Preferably, when carrying out a method according to the present invention the product (i.e. foodstuff) is produced without increasing or substantially increasing the free fatty acids in the foodstuff.
The term “transferase” as used herein is interchangeable with the term “lipid acyltransferase”.
The term “galactolipid transferase activity” as used herein means the ability of the enzyme to catalyse the transfer of an acyl group from a galactolipid donor to an acceptor molecule (other than water), such as glycerol for instance.
Likewise, the term “phospholipids transferase activity” as used herein means the ability of the enzyme to catalyse the transfer of an acyl group from a phospholipids donor to an acceptor molecule (other than water), such as glycerol for instance.
The term “an increased ratio of galactolipase transferase activity compared with phospholipid transferase activity” as used herein means the variant enzyme when compared with the parent enzyme is able to catalyse galactolipid transferase at a higher rate compared with phospholipid transferase. This may mean that both galactolipid transferase activity and phospholipid transferase activity are increased compared with the parent enzyme or that galactolipid transferase activity is increased whilst phospholipid transferase activity is decreased compared with the parent enzyme. It is the final relation between the two activities which is important.
Suitably, the lipid acyltransferase as defined herein catalyses one or more of the following reactions: interesterification, transesterification, alcoholysis, hydrolysis.
The term “interesterification” refers to the enzymatic catalysed transfer of acyl groups between a lipid donor and lipid acceptor, wherein the lipid donor is not a free acyl group.
The term “transesterification” as used herein means the enzymatic catalysed transfer of an acyl group from a lipid donor (other than a free fatty acid) to an acyl acceptor (other than water).
As used herein, the term “alcoholysis” refers to the enzymatic cleavage of a covalent bond of an acid derivative by reaction with an alcohol ROH so that one of the products combines with the H of the alcohol and the other product combines with the OR group ofthe alcohol.
As used herein, the term “alcohol” refers to an alkyl compound containing a hydroxyl group.
As used herein, the term “hydrolysis” refers to the enzymatic catalysed transfer of an acyl group from a lipid to the OH group of a water molecule. Acyl transfer which results from hydrolysis requires the separation of the water molecule.
The term “galactolipid hydrolytic activity” as used herein means the the ability of the enzyme to catalyse the hydrolysis of a galactolipid by transferring an acyl group from the galactolipid to the OH group of a water molecule.
Similarly, the term “phospholipid hydrolytic activity” as used herein means the the ability of the enzyme to catalyse the hydrolysis of a phospholipid by transferring an acyl group from the phospholipid to the OH group of a water molecule.
The term “an increased ratio of galactolipase transferase activity compared with galacolipid hydrolysis activity” as used herein means the variant enzyme when compared with the parent enzyme is able to catalyse galactolipid transferase at a higher rate compared with galactolipid hydrolysis. This may mean that both galactolipid transferase activity and galactolipid hydrolysis activity are increased compared with the parent enzyme or that galactolipid transferase activity is increased whilst galactolipid hydrolysis activity is decreased compared with the parent enzyme. It is the final relation between the two activities which is important.
The term “without increasing or without substantially increasing the free fatty acids” as used herein means that preferably the lipid acyl transferase according to the present invention has 100% transferase activity (i.e. transfers 100% of the acyl groups from an acyl donor onto the acyl acceptor, with no hydrolytic activity); however, the enzyme may transfer less than 100% of the acyl groups present in the lipid acyl donor to the acyl acceptor. In which case, preferably the acyltransferase activity accounts for at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity.
The % transferase activity (i.e. the transferase activity as a percentage of the total enzymatic activity) may be determined by the following protocol:
Protocol for the determination of % acyltransferase activity:
A foodstuff to which a lipid acyltransferase according to the present invention has been added may be extracted following the enzymatic reaction with CHCl;:CH;O0H 2:1 and the organic phase containing the lipid material is isolated and analysed by
GLC according to the procedure detailed hereinbelow. From the GLC analysis (and if necessary HPLC analysis) the amount of free fatty acids and one or more of sterol/stanol esters; carbohydrate esters, protein esters; diglycerides; or monoglycerides are determined. A control foodstuff to which no enzyme according to the present invention has been added, is analysed in the same way.
Calculation:
From the results of the GLC (and optionally HPLC analyses) the increase in free fatty acids and sterol/stanol esters and/or carbohydrate esters and/or protein esters and/or diglycerides and/or monoglycerides can be calculated:
A % fatty acid = % Fatty acid(enzyme) - % fatty acid(control); Mv fatty acid = average molecular weight of the fatty acids;
A = A % sterol ester/Mv sterol ester (where A % sterol ester = % sterol/stanol ester(enzyme) - % sterol/stanol ester(control) and Mv sterol ester = average molecular weight of the sterol/stanol esters) — applicable where the acyl acceptor is a sterol and/or stanol;
B= A % carbohydrate ester/Mv carbohydrate ester (where A % carbohydrate ester = % carbohydrate ester(enzyme) - % carbohydrate ester(control) and Mv carbohydrate ester
N = average molecular weight of the carbohydrate ester) - applicable where the acyl acceptor is a carbohydrate;
C = A % protein ester/Mv protein ester (where A % protein ester = % protein ester(enzyme) - % protein ester(control) and Mv protein ester = average molecular weight of the protein ester) — applicable where the acyl acceptor is a protein; and
D = absolute value of diglyceride and/or monoglyceride/Mv di/monoglyceride (where
A% diglyceride and/or monoglyceride = % diglyceride and/or monoglyceride (enzyme) - % diglyceride and/or monoglyceride (control) and Mv di/monoglyceride = average molecular weight of the diglyceride and/or monoglyceride) — applicable where the acyl acceptor is glycerol.
The transferase activity is calculated as a percentage of the total enzymatic activity: % transferase activity = A*+B*+C*+D* x 100
A* + B* + C* + D*+A % fatty acid/(Mv fatty acid) * . delete as appropriate.
The amino acids which fall within the terms “non-polar”, “polar — uncharged”, “polar — charged” are given in the table below, as are the amino acids falling within the terms “aliphatic” and “aromatic”. The term “polar” refers to both “polar — uncharged” and “polar — charged” amino acids.
Polar — uncharged CSTM
Ne
ZEEE LL
LL
I LAA
GLC analysis
Perkin Elmer Autosystem 9000 Capillary Gas Chromatograph equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 p film thickness 5% phenyl-methyl- silicone (CP Sil 8 CB from Chrompack).
Carrier gas: Helium.
Injector. PSSI cold split injection (initial temp 50°C heated to 385°C), volume 1.0ul
Detector FID: 395°C :
Oven program: 1 2 3
Oven temperature, °C. 90 280 350
Isothermal, time, min. 1 0 10
Temperature rate, °C/min. 15 4
Sample preparation: 30 mg of sample was dissolved in 9 ml Heptane:Pyridin, 2:1 containing internal standard heptadecane, 0.5 mg/ml. 300ul sample solution was transferred to a crimp vial, 300 pl MSTFA (N-Methyl-N-trimethylsilyl- trifluoraceamid) was added and reacted for 20 minutes at 60°C.
Calculation: Response factors for mono-di-triglycerides and free fatty acid were determined from Standard 2 (mono-di-triglyceride), for Cholesterol, Cholesteryl palmitate and Cholesteryl stearate the response factors were determined from pure reference material (weighing for pure material 10mg).
The present invention may provide one or more of the following unexpected technical effects in egg products, particularly mayonnaise: an improved heat stability during pasteurisation; improved organoleptic properties, an improved consistency.
Variant enzymes with increased phospholipid transferase activity, particularly with increased tranferase activity between a phospholipid and a sterol and/or stanol, such as cholesterol, may be particularly useful in methods for producing lysophospholipids and/or for enzymatic degumming of edible oils and/or for the production of egg products with improved emulsification properties and/or health benefits.
For use in methods of enzymatic degumming, variants with an increased absolute phospholipid transferase to sterol activity are preferred.
Suitably, the present invention may provide one or more of the following unexpected technical effects in egg or in egg products: improved stability of emulsion; thermal stability of emulsion; improved flavour; reduced mal-odour; improved thickening properties, improved consistency.
The present invention may provide one or more of the following unexpected technical effects in dough and/or baked products: an improved specific volume of either the dough or the baked products (for example of bread and/or of cake); an improved dough stability; an improved crust score (for example a thinner and/or crispier bread
S crust), an improved crumb score (for example a more homogenous crumb distribution and/or a finer crumb structure and/or a softer crumb); an improved appearance (for example a smooth surface without blisters or holes or substantially without blisters or holes); a reduced staling; an enhanced sofiness; an improved odour; an improved taste.
Suitably, the present invention may provide one or more of the following unexpected technical effects in a foodstuff: an improved appearance, an improved mouthfeel, an improved stability, in particular an improved thermal stability, an improved taste, an improved softness, an improved resilience, an improved emulsification.
Suitably, the present invention may provide one or more of the following unexpected technical effects in dairy products, such as ice cream for example: an improved mouthfeel (preferably a more creamy mouthfeel); an improved taste; an improved meltdown.
Specific technical effects associated with the use of a lipid acyltransferase as defined herein in the preparation of a foodstuff are listed in the table below:
Foodstuff [Effect 1 Strengthens dough and increases mechanical
Bread, Muffins and|resistance and increases water absorption capacity
Doughnuts and/or increases volume of bakery products and maintains softness of crumb and/or reduces blisters on the bread surface.
Prevents spoiling during refrigeration
Sponge cake Makes good cake volume and/or a uniform soft texture 4 | Biscuit, cracker and | Makes stable emulsions of fat and/or prevents cookie stickiness to the machine and/or prevents blooming of high fat products
Batter and breading mproves texture of fried products. 6 [Noodles | Prevents dough from sticking to the machine
Cl] and/or increases water content, and/or decreases cooking loss
Prevent noodles form adhering to each other
Hi Dough conditioner prevents adhesion on cooking.
Custard cream Makes starch paste with a smooth and creamy texture, and/or prevents dehydration. 10 | Coffec whitener | Prevent oil and water separation
Provides stable emulsion
Prevents or reduced blooming
Caramel, candy and | Improves emulsification of molten sugar and oil nougat and/or prevents separation of oil. 1 | Processed meat, | Improves water holding capacity of sausages and 4 | sausages pressed ham, and/or prevents separation of oil phase of pastes and pété.
Suitably, the present invention may provide one or more of the following unexpected technical effects in cheese: a decrease in the oiling-off effect in cheese; an increase in cheese yield; an improvement in flavour; a reduced mal-odour; a reduced “soapy” taste.
In one aspect, the present invention is based in part on the realisation that yields of foods — such as cheese - may be improved by the use of a lipid acyl transferase. In addition or alternatively, the flavour, texture, oxidative stability and/or shelf life of the food may be improved. In addition or alternatively, the food may have a reduced cholesterol level or enhanced content of phytosterol/stanol esters.
The present invention in one aspect may provide a food additive composition comprising a lipid acyl transferase as defined herein.
The present invention may in another aspect provide a cosmetic composition comprising a lipid acyl transferase as defined herein.
In addition, the present invention may provide the use of an acyltransferase as defined herein to produce a cosmetic composition.
ADVANTAGES
Variant transferases of the present invention have one or more of the following advantageous properties compared with the parent enzyme: i) an increased activity on polar lipids and/or an increased activity on polar lipids compared to triglycerides. ii) an increased activity on galactolipids (glycolipids), such as one or more of digalactosyl diglyceride (DGDG) and/or monogalactosyl diglyceride (MGDG). iii) an increased ratio of activity on galactolipids (glycolipids) compared to either phospholipids and/or triglycerides
Preferably variant transferases of the invention have increased activity on digalactosyl diglyceride (DGDG) and/or monogalactosyl diglyceride MGDG).
Preferably variant transferases of the present invention has increased activity on
DGDG and/or MGDG and decreased activity on DGMG and/or MGMG.
The variant transferases of the invention may also have an increased activity on triglycerides.
The variant transferases of the invention may also have an increased activity on phospholipids, such as lecithin, including phosphatidyl choline.
Variant transferases of the present invention may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides.
The term polar lipid refers to the polar lipids usually found in a dough, preferably galactolipids and phospholipids.
When used in preparation of a dough or baked product the variant transferase of the invention may result in one or more of the following unexpected technical effects in dough and/or baked products: an improved specific volume of either the dough or the baked products (for example of bread and/or of cake); an improved dough stability; an improved crust score (for example a thinner and/or crispier bread crust), an improved crumb score (for example a more homogenous crumb distribution and/or a finer crumb structure and/or a softer crumb); an improved appearance (for example a smooth surface without blisters or holes or substantially without blisters or holes); a reduced staling; an enhanced softness; an improved odour; an improved taste.
ISOLATED
In one aspect, preferably the polypeptide or protein for use in the present invention is in an isolated form. The term “isolated” means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature.
PURIFIED
In one aspect, preferably the polypeptide or protein for use in the present invention is in a purified form. The term “purified” means that the sequence is in a relatively pure state — e.g. at least about 51% pure, or at least about 75%, or at least about 80%, or at least about 90% pure, or at least about 95% pure or at least about 98% pure.
CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE
A nucleotide sequence encoding either a polypeptide which has the specific properties as defined herein or a polypeptide which is suitable for modification may be isolated from any cell or organism producing said polypeptide. Various methods are well known within the art for the isolation of nucleotide sequences.
For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide.
If the amino acid sequence of the polypeptide is known, labelled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.
Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme- negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified.
In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. ef al (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes ef al (1984) EMBO J. 3, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.
The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in
Saiki RK er al (Science (1988) 239, pp 487-491).
NUCLEOTIDE SEQUENCES
The present invention also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term “nucleotide sequence” as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double- stranded or single-stranded whether representing the sense or antisense strand.
The term "nucleotide sequence" in relation to the present invention includes genomic
DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence.
In a preferred embodiment, the nucleotide sequence per se encoding a polypeptide having the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the “non-native nucleotide sequence”. In this regard, the term "native nucleotide sequence” means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. Thus, the polypeptide of the present invention can be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.
Preferably the polypeptide is not a native polypeptide. In this regard, the term "native polypeptide” means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence.
Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH ef al (1980) Nuc Acids Res Symp Ser 215-23 and Horn T ef al (1980) Nuc Acids Res Symp Ser 225-232).
MOLECULAR EVOLUTION
Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the © 10 sequence in order to prepare an enzyme in accordance with the present invention.
Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
A suitable method is disclosed in Morinaga et al (Biotechnology (1984) 2, p646-649).
Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151).
Instead of site directed mutagenesis, such as described above, one can introduce mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify PCR random mutagenesis kit from
Clontech. EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those described in EP 0 866 796. Error prone PCR technologies are suitable for the production of variants of lipid acyl transferases with preferred characterisitics.
W00206457 refers to molecular evolution of lipases.
A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as
Dnase I, and reassembling full nucleotide sequences coding for functional proteins.
Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for performing ‘shuffling’ can be found in EPO 752 008, EP1 138 763, EP1 103 606.
Shuffling can also be combined with other forms of DNA mutagenesis as described in
US 6,180,406 and WO 01/34835.
Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded polypeptide by various means. Using in silico and exo mediated recombination methods (see WO 00/58517, US 6,344,328, US 6,361,974), for example, molecular evolution can be performed where the variant produced retains very low homology to known enzymes or proteins. Such variants thereby obtained may have significant structural analogy to known transferase enzymes, but have very low amino acid sequence homology. '
As a non-limiting example, In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.
The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial 75 mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or in vitro, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability, altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature, pH, substrate
As will be apparent to a person skilled in the art, using molecular evolution tools an enzyme may be altered to improve the functionality of the enzyme.
Suitably, the lipid acyltransferase used in the invention may be a variant, i.e. may contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme. Variant enzymes retain at least 25%, 30%, 40%, 50 %, 60%, 70%, 80%, 90%, 95%, 97%, 99% homology with the parent enzyme. Suitable parent enzymes may include any enzyme with esterase or lipase activity. Preferably, the parent enzyme aligns to the pfam00657 consensus sequence.
In a preferable embodiment a variant lipid acyltransferase enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks.
Enzymes, such as lipases with no or low lipid acyltransferase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the transferase activity, thereby producing a lipid acyltransferase enzyme with significant transferase activity suitable for use in the compositions and methods of the present invention.
Suitably, the lipid acyltransferase for use in the invention may be a variant with enhanced enzyme activity on polar lipids, preferably phospholipids and/or glycolipids when compared to the parent enzyme. Preferably, such variants also have low or no activity on lyso polar lipids. The enhanced activity on polar lipids, phospholipids and/or glycolipids may be the result of hydrolysis and/or transferase activity or a combination of both.
Variant lipid acyltransferases for use in the invention may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent . enzyme.
Suitably the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.
Alternatively, the variant enzyme for use in the invention may have increased activity on triglycerides, and/or may also have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine, glycolipids, digalactosyl monoglyceride, monogalactosyl monoglyceride.
Variants of lipid acyltransferases are known, and one or more of such variants may be suitable for use in the methods and uses according to the present invention and/or in the enzyme compositions according to the present invention. By way of example only, variants of lipid acyltransferases are described in the following references may be used in accordance with the present invention: Hilton & Buckley J Biol. Chem. 1991 Jan 15: 266 (2): 997-1000; Robertson ef al J. Biol. Chem. 1994 Jan 21; 269(3):2146-50;
Brumlik ef al J. Bacteriol 1996 Apr; 178 (7): 2060-4; Peelman et al Protein Sci. 1998
Mar; 7(3):587-99.
AMINO ACID SEQUENCES
The present invention also encompasses amino acid sequences of polypeptides having the specific properties as defined herein.
As used herein, the term “amino acid sequence” is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”.
The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.
Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques.
One suitable method for determining amino acid sequences from isolated polypeptides is as follows:
Purified polypeptide may be freeze-dried and 100 pg of the freeze-dried material may be dissolved in 50 pl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50°C following overlay with nitrogen and addition of 5 ul of 45 mM dithiothreitol.
After cooling to room temperature, 5 pl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen. 135 ul of water and 5 pg of endoproteinase Lys-C in 5 pl of water may be added to the above reaction mixture and the digestion may be carried out at 37°C under nitrogen for 24 hours.
The resulting peptides may be separated by reverse phase HPLC on a VYDAC C18 column (0.46x15cm; 10pm; The Separation Group, California, USA) using solvent A: 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C18 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Applied Biosystems, California, USA).
SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY
The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a “homologous sequence(s)”). Here, the term “homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term “homology” can be equated with ““identity™.
The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.
In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.
However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG
Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and 4 for each extension.
Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux et al 1984 Nuc. Acids Research 12 p387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4™ Ed - Chapter 18),
FASTA (Altschul ef al 1990 J. Mol. Biol. 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called
BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).
Although the final % homology can be measured in terms of identity, the alignment : process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the
BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as
BLOSUMG62.
Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS™ (Hitachi Software), based on an algorithm, analogous to
CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).
Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.
The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is rar ped Vee a mgle Lint en Fane meine acide dnctude aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.
Conservative substitutions may be made, for example according to the Table below.
Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
ALIPHATIC Non-polar (GAP |] oT : Polar — uncharged
TTT ee
Foe LL
I owe | [wey
The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid omithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.
Replacements may also be made by unnatural amino acids.
Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or - alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art.
For the avoidance of doubt, “the peptoid form” is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue’s nitrogen atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.
Nucleotide sequences for use in the present invention or encoding a polypeptide ‘having the specific properties defined herein may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences.
The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences discussed herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.
Polynucleotides which are not 100% homologous to the sequences of the present : invention but fall within the scope of the invention can be obtained in a number of ways.
Other variants of the sequences described herein may be obtained for example by probing
DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.
Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention.
Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variantshomologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.
The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.
Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.
Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels,
or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein. 5 .
Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.
In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.
Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.
HYBRIDISATION
The present invention also encompasses sequences that are complementary to the sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto.
The term “hybridisation” as used herein shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.
The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof,
The present invention also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences discussed herein.
Hybridisation conditions are based on the melting temperature (Tm) of the nucleotide binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning
Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.
Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe); high stringency at about 5°C to 10°C below Tm; intermediate stringency at about 10°C to 20°C below Tm; and low stringency at about 20°C to 25°C below Tm.
As will be understood by those of skill in the art, a maximum stringency hybridisation can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.
Preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.
More preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na-citrate pH 7.0}) to nucleotide sequences encoding polypeptides having the specific properties as defined herein.
The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).
The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).
Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed herein under conditions of intermediate to maximal stringency.
In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).
In a more preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under high stringent conditions (e.g. 65°C and 0.1xSSC).
EXPRESSION OF POLYPEPTIDES
A nucleotide sequence for use in the present invention or for encoding a polypeptide having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host cell. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.
The polypeptide produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.
EXPRESSION VECTOR
The term "expression vector” means a construct capable of in vivo or in vitro expression.
Preferably, the expression vector is incorporated in the genome of the organism. The term “incorporated” preferably covers stable incorporation into the genome.
The nucleotide sequence of the present invention or coding for a polypeptide having the specific properties as defined herein may be present in a vector, in which the nucleotide sequence is operably linked to regulatory sequences such that the regulatory sequences are capable of providing the expression of the nucleotide sequence by a suitable host organism, i.e. the vector is an expression vector.
The vectors of the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide having the specific properties as defined herein.
The choice of vector, e.g. plasmid, cosmid, virus or phage vector, will often depend on the host cell into which it is to be introduced.
The vectors may contain one or more selectable marker genes — such as a gene which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Alternatively, the selection may be accomplished by co-transformation (as described in W091/17243).
Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell.
Thus, in a further embodiment, the invention provides a method of making nucleotide sequences of the present invention or nucleotide sequences encoding polypeptides having the specific properties as defined herein by introducing a nucleotide sequence into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.
The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMBI1 and pLJ702.
REGULATORY SEQUENCES
In some applications, a nucleotide sequence for use in the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein may be operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.
The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
The term “regulatory sequences” includes promoters and enhancers and other expression regulation signals.
The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.
Enhanced expression of the nucleotide sequence encoding the enzyme having the specific properties as defined herein may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.
Preferably, the nucleotide sequence of the present invention may be operably linked to at least a promoter.
Examples of suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art.
CONSTRUCTS
The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shl-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention.
The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.
The construct may even contain or express a marker which allows for the selection of the genetic construct.
For some applications, preferably the construct comprises at least a nucleotide sequence of the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter.
HOST CELLS
The term “host cell” - in relation to the present invention includes any cell that comprises either a nucleotide sequence encoding a polypeptide having the specific properties as defined herein or an expression vector as described above and which is used in the recombinant production of a polypeptide having the specific properties as defined herein.
Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence of the present invention or a nucleotide sequence that expresses a polypeptide having the specific properties as defined herein.
The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells. Preferably, the host cells are not human cells.
Examples of suitable bacterial host organisms are gram negative bacterium or gram positive bacteria.
Depending on the nature of the nucleotide sequence encoding a polypeptide having the specific properties as defined herein, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred.
In general, yeast cells are preferred over fungal cells because they are easier to manipulate, However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.
The use of suitable host cells, such as yeast, fungal and plant host cells — may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.
The host cell may be a protease deficient or protease minus strain.
ORGANISM
The term "organism" in relation to the present invention includes any organism that could comprise a nucleotide sequence according to the present invention or a nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom.
Suitable organisms may include a prokaryote, fungus, yeast or a plant.
The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a polypeptide having the specific properties as defined herein within the organism.
Preferably the nucleotide sequence is incorporated in the genome of the organism.
The term “transgenic organism” does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.
Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or the products thereof. For example the transgenic organism can also comprise a nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a heterologous promoter.
TRANSFORMATION OF HOST CELLS/ORGANISM
As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism.
Examples of suitable prokaryotic hosts include E. coli and Bacillus subtilis.
Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook er al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.
In another embodiment the transgenic organism can be a yeast.
Filamentous fungi cells may be transformed using various methods known in the art — such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of Aspergillus as a host microorganism is described in EP 0 238 023.
Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus (Annu Rev Plant Physiol
Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech
March/April 1994 17-27). Further teachings on plant transformation may be found in
EP-A-0449375.
General teachings on the transformation of fungi, yeasts and plants are presented in following sections.
TRANSFORMED BACTERIA
A host organism may be a bacterium, such as Streptomyces, Bacillus subtilis or E.coli.
Suitable methods of heterologous expression in E.coli are disclosed in W004/064537.
Suitable methods of heterologous expression in Bacillus are disclosed in
W002/214490. Examples of suitable bacterial host organisms are gram positive bacterial species such as Bacillaceae, including Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus lautus, Bacillus megaterium and Bacillus thuringiensis, Streptomyces species, such as Streptomyces murinus, lactic acid bacterial species, including Lactococcus spp., such as Lactococcus lactis, Lactobacillus spp., including Lactobacillus rewteri, Leuconostoc spp.,
Pediococcus spp. and Streptococcus spp. Alternatively, strains of a gram-negative bacterial species belonging to Enterobacteriaceae, including E. coli, or to
Pseudomonadaceae can be selected as the host organism.
TRANSFORMED FUNGUS
A host organism may be a fungus - such as a filamentous fungus. Examples of suitable such hosts include any member belonging to the genera Thermomyces, Acremonium,
Aspergillus, Penicillium, Mucor, Neurospora, Trichoderma and the like.
Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to NV. crassa is found, for example in Davis and de Serres, Methods Enzymol (1971) 17A: 79-143.
Further teachings on transforming filamentous fungi are reviewed in US-A-5674707.
In one aspect, the host organism can be of the genus Aspergillus, such as Aspergillus niger.
A transgenic Aspergillus according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli $.D., Kinghorn J.R.( Editors) Aspergillus: 50 years on.
Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).
Gene expression in filamentous fungi has been reviewed in Punt ef al. (2002) Trends
Biotechnol 2002 May;20(5):200-6, Archer & Peberdy Crit Rev Biotechnol (1997) 17(4):273-306.
TRANSFORMED YEAST
In another embodiment, the transgenic organism can be a yeast.
A review of the principles of heterologous gene expression in yeast are provided in, for example, Methods Mol Biol (1995), 49:341-54, and Curr Opin Biotechnol (1997)
Oct;8(5):554-60
In this regard, yeast — such as the species Saccharomyces cerevisi or Pichia pastoris (see
FEMS Microbiol Rev (2000 24(1):45-66), may be used as a vehicle for heterologous gene expression.
A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol §, Anthony H Rose and
J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).
For the transformation of yeast, several transformation protocols have been developed.
For example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen ef al., (1978, Proceedings of the National
Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).
The transformed yeast cells may be selected using various selective markers — such as auxotrophic markers dominant antibiotic resistance markers.
A suitable yeast host organism can be selected from the biotechnologically relevant yeasts species such as, ‘but not limited to, yeast species selected from Pichia spp., Hansenula spp., Kluyveromyces, Yarrowinia spp., Saccharomyces spp., including S. cerevisiae, or Schizosaccharomyce spp. including Schizosaccharomyce pombe.
A strain of the methylotrophic yeast species Pichia pastoris may be used as the host organism.
In one embodiment, the host organism may be a Hansenula species, such as H. polymorpha (as described in W0O01/39544).
TRANSFORMED PLANTS/PLANT CELLS
A bost organism suitable for the present invention may be a plant. A review of the general techniques may be found in articles by Potrykus (4nnu Rev Plant Physiol Plant
Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27), or in WOO01/16308. The transgenic plant may produce enhanced levels of phytosterol esters and phytostanol esters, for example.
Therefore the present invention also relates to a method for the production of a transgenic plant with enhanced levels of phytosterol esters and phytostanol esters, comprising the steps of transforming a plant cell with a lipid acyltransferase as defined herein (in particular with an expression vector or construct comprising a lipid acyltransferase as defined herein), and growing a plant from the transformed plant cell.
SECRETION
Often, it is desirable for the polypeptide to be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the context of the present invention.
Typical examples of heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the a-factor gene (yeasts e.g. Saccharomyces,
Kluyveromyces and Hansenula) or the a-amylase gene (Bacillus).
DETECTION
A variety of protocols for detecting and measuring the expression of the amino acid sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays.
A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures.
Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A- 4,277,437; US-A-4,275,149 and US-A-4,366,241.
Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.
FUSION PROTEINS
A polypeptide having the specific properties as defined herein may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and p-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences.
Preferably the fusion protein will not hinder the activity of the protein sequence.
Gene fusion expression systems in E. coli have been reviewed in Curr. Opin.
Biotechnol. (1995) 6(5):501-6.
In another embodiment of the invention, the amino acid sequence of a polypeptide having the specific properties as defined herein may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.
The invention will now be described, by way of example only, with reference to the following Figures and Examples.
Figure 1 shows a pfam00657 consensus sequence from database version 6 (SEQ ID
No. 1);
Figure 2 shows an amino acid sequence (SEQ ID No. 2) obtained from the organism
Aeromonas hydrophila (P10480; GI:121051). This amino acid sequence is a reference enzyme, which may be a parent enzyme in accordance with the present invention;
Figure 3 shows an amino acid sequence (SEQ ID No. 3) obtained from the organism
Aeromonas salmonicida (AAG098404; GI1:9964017);
Figure 4 shows an amino acid sequence (SEQ ID No. 4) obtained from the organism
Streptomyces coelicolor A3(2) (Genbank accession number NP_631558);
Figure 5 shows an amino acid sequence (SEQ ID No. 5) obtained from the organism
Streptomyces coelicolor A3(2) (Genbank accession number: CACA2140);
Figure 6 shows an amino acid sequence (SEQ ID No. 6) obtained from the organism
Saccharomyces cerevisiae (Genbank accession number P41734);
Figure 7 shows an alignment of selected sequences to pfam00657 consensus sequence;
Figure 8 shows a pairwise alignment of SEQ ID No. 3 with SEQ ID No. 2 showing 93% amino acid sequence identity. The signal sequence is underlined. + denotes differences. The GDSX motif containing the active sité serine 16, and the active sites aspartic acid 116 and histidine 291 are highlighted (see shaded regions). Numbers after the amino acid is minus the signal sequence;
Figure 9 shows a nucleotide sequence (SEQ ID No. 7) encoding a lipid acyl transferase according to the present invention obtained from the organism Aeromonas hydrophila;
Figure 10 shows a nucleotide sequence (SEQ ID No. 8) encoding a lipid acyl transferase according to the present invention obtained from the organism Aeromonas salmonicida,
Figure 11 shows a nucleotide sequence (SEQ ID No. 9) encoding a lipid acyl transferase according to the present invention obtained from the organism
Streptomyces coelicolor A3(2) (Genbank accession number
NC_003888.1:8327480..8328367);
Figure 12 shows a nucleotide sequence (SEQ ID No. 10) encoding a lipid acyl transferase according to the present invention obtained from the organism
Streptomyces coelicolor A3(2) (Genbank accession number
AL939131.1:265480..266367);
Figure 13 shows a nucleotide sequence (SEQ ID No. 11) encoding a lipid acyl transferase according to the present invention obtained from the organism
Saccharomyces cerevisiae (Genbank accession number Z75034);
Figure 14 shows an amino acid sequence (SEQ ID No. 12) obtained from the organism
Ralstonia (Genbank accession number: AL646052);
Figure 15 shows a nucleotide sequence (SEQ ID No. 13) encoding a lipid acyl transferase according to the present invention obtained from the organism Ralstonia;
Figure 16 shows SEQ ID No. 14. Scoel NCBI protein accession code CAB39707.1
GI:4539178 conserved hypothetical protein [Streptomyces coelicolor A3(2)];
Figure 17 shows a nucleotide sequence shown as SEQ ID No. 15 encoding NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [Streptomyces coelicolor A3(2)];
Figure 18 shows an amino acid shown as SEQ ID No. 16. Scoe2 NCBI protein accession code CACO01477.1 GI1:9716139 conserved hypothetical protein [Streptomyces coelicolor A3(2)];
Figure 19 shows a nucleotide sequence shown as SEQ ID No. 17 encoding Scoe2
NCBI protein accession code CAC01477.1 GI:9716139 conserved hypothetical protein [Streptomyces coelicolor A3(2)];
Figure 20 shows an amino acid sequence (SEQ ID No. 18) Scoe3 NCBI protein accession code CAB88833.1 GL:7635996 putative secreted protein. [Streptomyces coelicolor A3(2)];
Figure 21 shows a nucleotide sequence shown as SEQ ID No. 19 encoding Scoe3
NCBI protein accession code CAB88833.1 GI:7635996 putative secreted protein. [Streptomyces coelicolor A3(2)];
Figure 22 shows an amino acid sequence (SEQ ID No. 20) Scoed NCBI protein accession code CAB89450.1 GI:7672261 putative secreted protein. [Streptomyces coelicolor A3(2)];
Figure 23 shows an nucleotide sequence shown as SEQ ID No. 21 encoding Scoe4
NCBI protein accession code CAB89450.1 GI:7672261 putative secreted protein. [Streptomyces coelicolor A332);
Figure 24 shows an amino acid sequence (SEQ ID No. 22) Scoe5 NCBI protein accession code CAB62724.1 GI:6562793 putative lipoprotein [Streptomyces coelicolor A3(2)];
Figure 25 shows a nucleotide sequence shown as SEQ ID No. 23, encoding Scoe5
NCBI protein accession code CAB62724.1 G1:6562793 putative lipoprotein [Streptomyces coelicolor A3(2)];
Figure 26 shows an amino acid sequence (SEQ ID No. 24) Srim! NCBI protein accession code AAK84028.1 GI:15082088 GDSL-lipase [Streptomyces rimosus];
Figure 27 shows a nucleotide sequence shown as SEQ ID No. 25 encoding Sriml
NCBI protein accession code AAKS84028.1 GI:15082088 GDSL-lipase [Streptomyces rimosus];
Figure 28 shows an amino acid sequence (SEQ ID No. 26) - a lipid acyl transferase from Aeromonas hydrophila (ATCC #7965);
Figure 29 shows a nucleotide sequence (SEQ ID No. 27) encoding a lipid acyltransferase from Aeromonas hydrophila (ATCC #7965);
Figure 30 shows an amino acid sequence (SEQ ID No. 28) of a lipid acyltransferase from Aeromonas salmonicida subsp. Salmonicida (ATCC#14174);
Figure 31 shows a nucleotide sequence (SEQ ID No. 29) encoding a lipid acyltransferase from Aeromonas salmonicida subsp. Salmonicida (ATCC#14174);
Figure 32 shows that homologues of the Aeromonas genes can be identified using the basic local alignment search tool service at the National Center for Biotechnology
Information, NTH, MD, USA and the completed genome databases. The GDSX motif was used in the database search and a number of sequences/genes potentially encoding enzymes with lipolytic activity were identified. Genes were identified from the genus
Streptomyces, Xanthomonas and Ralstonia. As an example below, the Ralstonia solanacearum was aligned to the Aeromonas salmonicida (satA) gene. Pairwise alignment showed 23% identity. The active site serine is present at the amino terminus and the catalytic residues histidine and aspartic acid can be identified;
Figure 33 shows the Pfam00657.11 [family 00657, database version 11] consensus sequence (hereafter called Pfam consensus) and the alignment of various sequences to the Pfam consensus sequence. The arrows indicate the active site residues, the underlined boxes indicate three of the homology boxes indicated by [Upton C and
Buckley JT (1995) Trends Biochem Sci 20; 179-179]. Capital letters in the Pfam consensus indicate conserved residues in many family members. The — symbol indicates a position where the hidden Markov model of the Pfam consensus expected to find a residue but did not, so a gap is inserted. The . symbol indicates a residue without a corresponding residue in the Pfam consensus. The sequences are the amino acid sequences listed in Figures 16, 18, 20, 22, 24, 26, 28 and 30.
Figure 34 shows the Pfam00657.11 [family 00657, database version 11] consensus sequence (hereafter called Pfam consensus) and the alignment of various sequences to the Pfam consensus sequence. The arrows indicate the active site residues, the underlined boxes indicate three of the homology boxes indicated by [Upton C and
Buckley JT (1995) Trends Biochem Sci 20; 179-179]. Capital letters in the Pfam consensus indicate conserved residues in many family members. The — symbol indicates a position where the hidden Markov model of the Pfam consensus expected to find a residue but did not, so a gap is inserted. The . symbol indicates a residue without a corresponding residue in the Pfam consensus. The sequences are the amino acid sequences listed in Figures 2, 16, 18, 20, 26, 28 and 30. All these proteins were found to be active against lipid substrates.
Figure 35 shows an amino acid sequence (SEQ ID No. 30) of the fusion construct used for mutagenesis of the Aeromonas hydrophila lipid acyltransferase gene in Example 7.
The underlined amino acids is a xylanase signal peptide;
Figure 36 shows a nucleotide sequence (SEQ ID No. 31) encoding a lipid acyltransferase enzyme from Aeromonas hydrophila including a xylanase signal peptide;
Figure 37 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from
Streptomyces (SEQ ID No. 32);
Figure 38 shows a polypeptide sequence of a lipid acyltransferase enzyme from
Streptomyces (SEQ ID No. 33);
Figure 39 shows a polypeptide sequence of a lipid acyltransferase enzyme from
Termobifida (SEQ ID No. 34);
Figure 40 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from Termobifida (SEQ ID No. 35);
Figure 41 shows a polypeptide sequence of a lipid acyltransferase enzyme from
Termobifida (SEQ ID No. 36);
Figure 42 shows a polypeptide of a lipid acyltransferase enzyme from
Corynebacterium\effciens\ GDSx 300 aa (SEQ ID No. 37);
Figure 43 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from
Corynebacterium\effciens\ GDSx 300 aa (SEQ ID No. 38);
Figure 44 shows a polypeptide of a lipid acyltransferase enzyme from
Novosphingobium\aromaticivorans\ GDSx 284 aa (SEQ ID No. 39);
Figure 45 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from Novosphingobium\aromaticivorans\ GDSx 284 aa (SEQ ID No. 40);
Figure 46 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces coelicolor GDSx 268 aa (SEQ ID No. 41);
Figure 47 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from
Streptomyces coelicolor\ GDSx 268 aa (SEQ ID No. 42);
Figure 48 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces avermitilis \ GDSx 269 aa (SEQ ID No. 43);
Figure 49 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from
Streptomyces avermitilis \ GDSx 269 aa (SEQ ID No. 44);
Figure 50 shows a polypeptide of a lipid acyltransferase enzyme from Streptomyces (SEQ ID No. 45);
Figure 51 shows a nucleotide sequence encoding a lipid acyltransferase enzyme from
Streptomyces (SEQ ID No. 46);
Figure 52 shows a ribbon representation of the IIVN.PDB crystal structure which has glycerol in the active site. The Figure was made using the Deep View Swiss-PDB viewer;
Figure 53 shows 1IVN.PDB Crystal Structure — Side View using Deep View Swiss-
PDB viewer, with glycerol in active site - residues within 10A of active site glycerol are coloured black;
Figure 54 shows 1IVN.PDB Crystal Structure — Top View using Deep View Swiss-
PDB viewer, with glycerol in active site — residues within 104 of active site glycerol are coloured black;
Figure 55 shows alignment 1;
Figure 56 shows alignment 2;
Figures 57 and 58 show an alignment of 1IVN to P10480 (P10480 is the database sequence for A. hydrophila enzyme), this alignment was obtained from the PFAM database and used in the model building process;
Figure 59 shows an alignment where P10480 is the database sequence for Aeromonas hydrophila. This sequence is used for the model construction and the site selection.
Note that the full protein is depicted, the mature protein (equivalent to SEQ ID No. 2) starts at residue 19. A. sal is Aeromonas salmonicida (SEQ ID No. 28) GDSX lipase,
A. hyd is Aeromonas hydrophila (SEQ ID No. 26) GDSX lipase. The consensus sequence contains a * at the position of a difference between the listed sequences;
Figure 60 shows a typical set of 384 clones, the wild type control lies at the intersection of 0.9PC, 0.8DGDG; and
Figure 61 shows three areas of interest. Section 1 contains mutants with an increased ratio R but lower activity towards DGDG. Region 2 contains mutants with an increased ratio R and an increased DGDG activity. Region 3 contains clones with an increased PC or DGDG activity, but no increase in the ratio R.
EXAMPLE 1 odelling of Aeromonas hydrophila GDSx lipase on LIVN
The alignment of the Aeromonas hydrophila GDSX lipase amino acid sequence (P10480) to the Escherichia coli Tioesterase amino acid sequence (1IVN) and the
Aspergillus aculeatus rthamnogalacturonan acetylesterase amino acid sequence (1DEO) was obtained from the PFAM database in FASTA format. The alignment of
P10480 and 1IVN was fed into an automated 3D structure modeller (SWISS-
MODELLER server at www.expasy.org) together with the 1TVN.PDB crystal structure coordinates file FIGURE 52). The obtained model for P10480 was structurally aligned to the crystal structures coordinates of 1IVN.PDB and 1DEO.PDB using the Deep
View Swiss-PDB viewer (obtained from www.expasy.org/spdbv/) (FIGURE 53). The amino acid alignment obtained from the PFAM database (alignment 1 - (FIGURE 55)) was modified based on the structural alignment of 1DEO.PDB and 1IVN.PDB. This 95 alternative amino acid alignment is called alignment 2 (FIGURE 56).
The 1IVN.PDB structure contains a glycerol molecule. This molecule is considered to be in the active site because it is in the vicinity of the catalytic residues. Therefore, a selection can be made of residues that are close to the active site which, due to their vicinity, are likely to have an influence on substrate binding, product release, and/or catalysis. In the 1IVN.PDB structure, all amino acids within a 10 A sphere centered on the central carbon atom of the glycerol molecule in the active site were selected (amino acid set 1) (See Figure 53 and Figure 54).
The following amino acids were selected from the P10480 sequence; (1) all amino acids in P10480 corresponding to the amino acid set 1 in alignment 1; (2) all amino acids in P10480 corresponding to the amino acid set 1 in alignment 2; (3) from the overlay of the P10480 model and 1IVN all amino acids in the P10480 model within 124 from the glycerol molecule in 1TVN. All three groups combined give amino acid set 2.
Sequence P10480 was aligned to "AAG09804.1 G1:9964017 glycerophospholipid- cholesterol acyltransferase [Aeromonas salmonicida)" and the residues in AAG09804 corresponding to amino acid set 2 were selected to give amino acid set 3.
Setl,2,and3
Amino acid set 1:
Amino acid set 1 (note that these are amino acids in 1IVN — Figure 57 and Figure 58.)
Gly8. Asp9, Leull, Serl2, Tyrl5, Gly44, Asp45, Thr46, Glu69, Leu70, Gly71, Gly72,
Asn73. Asp74, Gly75, Leu76, Gn106, 1lel07, Argl108, Leul09, Pro110, Tyrll3,
Phel21, Phel39, Phe140, Met141, Tyr145, Met151, Aspl54, His157, Gly155, Ile 56,
Prol58
The highly conserved motifs, such as GDSx and catalytic residues, were deselected from set 1 (residues underlined). For the avoidance of doubt, set 1 defines the amino acid residues within 10A of the central carbon atom of a glycerol in the active site of the 1TVN model.
Amino acid set 2:
Amino acid set 2 (note that the numbering of the amino acids refers to the amino acids in the P10480 mature sequence)
Leul7, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn87, Asn88, Trpl11, Vall 12,
Alal14, Tyr117, Leul18, Prol56, Gly159, Gln160, Asnl61, Prol62, Serl63, Ala164, Argl65, Serl66, Glnl67, Lys168, Val169, Val170, Glul71, Alal72, Tyrl79, His180,
Asnl81, Met209, Leu210, Arg211, Asn215, Lys284, Met285, GIn289 and Val290.
Table of selected residues in Set 1 compared with Set 2:
IVN model P10480
Mature sequence residue a [sme
Gly8 Gly32
Asp9 | Asp33
Serl0 | Ser34
Leull |Leu35 Leul?7
Ser12 | Ser36 Serl8
Lys22
Met23
Tyrl5s | Gly58 Gly40
Gly44 | Asn98 Asn80
Asp45 | Pro99 Pro81
Thrd46 | Lys100 Lys82
Asn87
Asn88
Glu69 | Trp129 Trplll
Leu70 | Vall30 Valll2
Gly71 | Glyl3l
Gly72 | Alal32 Alall4
Asn73 | Asnl33
Asp74 | Aspl34
Gly75 | Tyrl35 Tyrll7
Leu76 | Leul36 Leull8
GIn106 Prol74 Prol156
Nle107 Gly177 Gly159 }
Argl08 GInl78 Gin160
Leul09 Asnl79 Asnlé6l
Prol10 180 to 190 | Pro162
Tyrl13 Ser163
Alal64
Argl65
Serl66
GIn167
Lys168
Vall69
Vall70
Glul71
Alal72
Phel2l | His198 | Tyr197 Tyrl79
His198 His180
Asn199 Asnl81
Phel39 | Met227 Met209
Phel40 | Leu228 Leu210
Metl41 | Arg229 Arg2ll
Tyr145 | Asn233 Asn215
Lys284
Metl51 | Met303 Met285
Aspl54 | Asp306
Gly155 | GIn307 GIn289
Nlel56 | Val308 Val290
His157 {| His309 i I
Amino acid set 3:
Amino acid set 3 is identical to set 2 but refers to the Aeromonas salmonicida (SEQ ID
No. 28) coding sequence, i.e. the amino acid residue numbers are 18 higher in set 3 as this reflects the difference between the amino acid numbering in the mature protein (SEQ ID No. 2) compared with the protein including a signal sequence (SEQ ID No. 28).
The mature proteins of Aeromonas salmonicida GDSX (SEQ ID No. 28) and
Aeromonas hydrophila GDSX (SEQ ID No. 26) differ in five amino acids. These are
Thr3Ser, GIn182Lys, Glu309Ala, Ser310Asn, Gly318-, where the salmonicida residue is listed first and the hydrophila residue is listed last (FIGURE 59). The hydrophila protein is only 317 amino acids long and lacks a residue in position 318. The
Aeromonas salmonicidae GDSX has considerably high activity on polar lipids such as galactolipid substrates than the Aeromonas hydrophila protein. Site scanning was performed on all five amino acid positions.
Amino acid set 4:
Amino acid set 4 is S3, Q182, E309, S310, and -318.
Amino acid set 5:
F138, D15N, S18G, S18V, Y30F, D116N, D116E, D157N, Y226F, D228N Y230F.
Amino acid set 6:
Amino acid set 6 is Ser3, Leul7, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87,
Asn88, Trplll, Valll2, Alall4, Tyr117, Leull8, Pro156, Glyl59, GIn160, Asnl61,
Prol62, Serl63, Alal64, Argl65, Ser166, GIn167, Lys168, Val169, Vall70, Glul71,
Alal72, Tyrl79, His180, Asnl8l, Gln182, Met209, Leu210, Arg2ll, Asn215,
Lys284, Met285, GIn289, Val290, Glu309, Ser310, -318.
The numbering of the amino acids in set 6 refers to the amino acids residues in P10480 (SEQ ID No. 2) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN.
Amino acid set 7:
Amino acid set 7 is Ser3, Leul7, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87,
Asn88, Trplll, Valll2, Alall4, Tyrl117, Leul18, Prol56, Gly159, GIn160, Asnl61,
Prol62, Serl63, Alal64, Argl65, Serl66, Ginl67, Lys168, Val169, Val170, Glul71,
Alal72, Tyrl79, His180, Asnl81, Glnl82, Met209, Leu210, Arg2ll, Asn215, Lys284, Met285, GIn289, Val290, Glu309, Ser310, -318, Y30X (where X is selected from A,C,D,E,G, , LK, L, M,N, P, Q,R,S, T, V, or W), Y226X (where X is selected from A, C,D,E,G,H,LK,L,M,N,P,QR, 8, T, V, or W), Y230X (where
X is selected from A, C,D, E, G, H, LK, L, M,N, P,Q, R, §, T, V, or W), S18X (where X is selected from A, C, D,E,F, H, 1, K,L,M,N,P,Q,R, T, Wor Y), DI57X (where X is selected from A, C,E,F,G,H,LLK,L,M,P, Q,R,S,T,V,WorY).
The numbering of the amino acids in set 7 refers to the amino acids residues in P10480 (SEQ ID No. 2) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN).
From the crystal structure one can obtain the secondary structure classification. That means, one can classify each amino acid as being part of an alpha-helix or a beta-sheet.
Figure 57 shows the PFAM alignment of 1DEO, 1IVN, and P10480 (the database
Aeromonas hydrophila). Added below each line of sequence is the structural classification.
The PFAM database contains alignments of proteins with low sequence identity.
Therefore, these alignments are not very good. Although the alignment algorithms (HAMMER profiles) are well suited for recognizing conserved motifs the algorithm is not very good on a detailed level. Therefore it is not surprising to find a disparity between the PFAM alignment and a structural alignment. As a skilled person would be readily aware, one can modify the PFAM alignment based on the structural data.
Meaning that one can align those structural elements that overlap.
FIGURE 55 shows the original PFAM alignment of 1DEO, 1IVN and P10480. Added to the alignment is the secondary structure information from the crystal structures of 1DEO and 1IVN. Alignment 2 in FIGURE 56 shows a manually modified alignment where the match between the secondary structure elements is improved. Based on conserved residues between either IDEO and P10480 or between 1TVN and P10480 the alignment was modified for P10480 as well. To easily distinguish the sequence blocks the sequence identifiers in alignment 2 have an extra m (IDEOm, 1IVNm,
P10480m). .
Alignment 3 is a mix of 1 and 2, it gives the alignment per block.
EXAMPLE 2: Construction of site scan libraries
The Quick Change Multi Site-Directed Mutagenesis Kit from Stratagene was used according to the manufacturers instruction. For each library a degenerate primer with one NNK or NNS (nucleotide abbreviations) codon was designed. Primer design was performed using the tools available on the Stratagene web site. Primer quality control was further confirmed using standard analysis tools which analyze the primer for the potential of forming hairpins or of forming primer-dimers.
The main concepts of the method are as follows; using a non-strand displacing high- fidelity DNA polymerase such as Pfu-Turbo and a single primer one will linearly amplify the DNA template. This is in contrast to the normal exponential amplification process of a PCR reaction. This linear amplification process ensures a low error frequency. The product is single stranded non-methylated DNA and double stranded hemi-methylated DNA. If the template is obtained from a suitable host organism, then the template is double stranded methylated DNA. This means that the template DNA can be digested with Dpn I endonuclease without digesting the product DNA.
Therefore upon transformation of the DNA into a suitable host only a very low frequency of the transformants with non-mutagenized plasmid.
EXAMPLE 3: Selection of winners from a site scan library
Two alternative approaches are described; library sequencing followed by analysis of unique amino acids, or library analysis followed by sequencing of the winners.
Selection of winners method 1; library sequencing followed by analysis of unique amino acids.
The transformation/expression shuttle vector used for generation of the site scanning libraries/variants in E. coli and expression of the variants in B. subtilis was derived from pDP66S, Penninaga ef al., ( Biochemistry (1995), 3368-3376), by replacement of the selection cassette to a kanamycin selection cassette. The vector used to insert the acyltransferase variant gene in place of the cgt gene down-stream of the P32 promoter. The vector uses the P32 promoter to drive expression of the acyl-transferase variant gene in B. subtilis.
The expression vector was transformed into nprE-, aprA- Bacillus subtillis DB104 (Kawamura and Doi, J. of Bacteriology Oct 1984, p442-444) using transformation methods, as described in Chapter 3, Molecular Biological Methods for Bacillus (Ed.
C.R. Harwood and S.M. Cutting), 1990. John Wiley & Sons Ltd. Chichester, UK).
Site scan libraries were constructed using a degenerate oligo containing one NNK codon, where K stands for Gor T and N stands for A, C, G, or T. This means that a set of clones constructed from an amplification reaction using an NNK primer (also known as 'a site scan library’) contains in principle 32 unique codons (4x4x2 = 32 combination options). Assuming no bias due, the number of clones that one needs to pick to have a 95% chance of picking every one of the 32 codons at least once is 95.
This can be calculated using the following formula
Formulal; n= {log (1c) }/ {log (1-0 }
Where n is the number of clones, ¢ is the fraction value of the confidence interval, for example the 95% confidence interval has a value of 0.95 and the 99% confidence interval has a fraction value of 0.99, and f is the frequency with which each individual codon occurs, which for an NNK primer is 1/32 or 0.03125. Solving the formula for n gives 94.36 or 95 clones. Ifa 95% confidence interval is deemed to be too low, or if one is unable to avoid bias in one or more steps of the library construction process, one can decide to assay or sequence more clones. For example, in formula 1, if n is set to 384, fto 1/32 or 0.03125 then the confidence interval ¢ is much larger than 99%. Even if 60% of the clones contain the same mutation or the wild type codon, then 363 clones will give a 99% confidence of obtaining all 32 codons. From this one can conclude that, 384 clones will have a 99% confidence of containing each of the 32 codons at least once.
A colony PCR was performed (a PCR reaction on a bacterial colony or on a bacterial liquid culture to amplify a fragment from a plasmid inside a bacterium, and subsequently sequencing that part of the fragment which has been mutagenised is an established procedure. Colony PCR can be routinely performed for sets of 96 due to the availability of prefabricated material (also known as Kits) for colony PCR, sequencing, and sequence purification. This entire procedure is offered as a service by several commercial companies such as AGOWA GmbH, Glienicker weg 185, D- 12489 Berlin, Germany.
After analysing the 96 sequence reactions, the individual clones were selected representing one for each codon that is available in the set of 96 sequences.
Subsequently, for each of the clones representing the mutants, 5 ml of LB broth (Casein enzymatic digest, 10 g/l; low-sodium Yeast extract, 5 g/L; Sodium Chloride, 5 g/l; Inert tableting aids, 2 g/l) supplemented with 50 mg/l kanamycin, was inoculated and incubated at 33 °C for 6 hours at 205 rpm. 0.7 ml of this culture was used to inoculate 50 ml of SAS substrate (KoHPOs, 10 g/l; MOPS (3-morpholinopropane sulfonic acid), 40 g/l; Sodium Chloride, 5 g/l; Antifoam (Sin 260), 5 drops/l; Soy flour degreased, 20 g/l; Biospringer 106 (100 % dw YE), 20 g/l) supplemented with SO mg/l kanamycin and a solution of high maltose starch hydrolysates (60 g/1). Incubation was continued for 40 hours at 33 °C and 180 rpm before the culture supernatant was separated by centrifugation at 19000 rpm for 30 min. The supernatant was transferred into a clean tube and directly used for the assay.
Selection of winners method 2; library screening followed by sequencing of the winners
Although one could choose to sequence 384 clones, one may also assay them and select improved variants before sequencing.
A number of issues should be considered when such a number of samples are screened. Without being exhaustive, although it is possible to select variants with altered activity on one substrate, the difference in expression level between 384 cultures can be substantial even if one uses a 384 well microtiter plate, resulting in a high background. Therefore, measuring two activities and selecting winners based on a change in ratio is a preferred method. To illustrate, if two activities have a certain ratio
R then regardless of the absolute amount of enzyme present, the ratio between the two activities will always be R. A change in the R value indicates a mutation that changed one activity relative to the second activity.
Figure 60 shows a data set obtained from the site scan library. The clones are all tested for activity towards phosphatidyl choline (PC) and digalactosyl diglyceride (DGDG).
All clones, which can be mutated or not, that exhibit no change in the R value will lie on a straight line with a certain margin of error. Disregarding these clones three groups of interest appear in Figure 61. .
Section 1 in Figure 61 contains all the clones that have a significantly higher R than the wild-type (not mutated) but lower overall DGDG activity. Section 2 contains those clones that have both a higher R value and a higher DGDG activity than the wild type.
Section 3 contains clones that do not have a higher R value, but that do have a significantly higher DGDG or PC activity.
If one is interested in variants with an increased activity towards DGDG then section 2 contains the most interesting variants and section 3 contains variants of interest as well. The variants in Section 3 which show a large increase in hydrolytic activity may be accompanied by a decrease in transferase activity.
One thing is worth noticing, if a specificity determining residue is hit, most of the 20 possible amino acids could yield a very different R value. However, if the library contains a large bias towards a single amino acid (for example 60% is Tyrosine) then all those variants will still lie on a straight line.
EXAMPLE 4 : Assays for PC and DGDG activity in a 384 well microtiter plate
Start material eo EM media o Plate with transformants e Plate with wild type e 384 plates e colony picker e Waco NEFA-C kit e PC and DGDG solutions in a 384 plate
Part 1 — picking colonies e Pick colonies into a 384 plate filled with EM medium eo Skip 4 wells and inoculate those with colonies containing the non-mutated backbone e Grow of at 30°C, 200 rpm shaking speed
Part 2 — Incubation on substrate eo Centrifuge the o/n grown plates; 2500 rpm, 20 min eo Transfer 10 pl supernatant from each well to 2 empty 384 plates e Add 5 pl 12.5 mM DGDG to one of the plates, add 5 pl 12.5 mM PC to the other plate o Incubate both plates 2 hrs at 37°C, shake at start to mix then stop the shaking ¢ Continue with the NEFA C procedure
Part 3 —NEFA-C procedure e Add 10 pl A solution e Incubate 10 min 37°C, 300 rpm e Add 20 ul B solution e Incubate 10 min 37°C, 300 rpm e Read the plate at 550 nm
Substrate composition — in mM 25 mM PC eller DGDG 10 mM CaCl, 60 mM Triton X 100 15 mM NaN3 :
20 mM Briton Robinson pH 5.0
EXAMPLE 5 Selected variants
Determination of enzyme activity
To determine the enzymatic activity towards various substrates 4 pl enzyme solution was incubated with 11 pl substrate for 60 minutes at 37°C. Subsequently the amount of free fatty acids was determined using the WACO NEFA-C kit. To the 15 pl enzyme-+substrate mix 75 pl NEFA solution A was added and incubated for 15 minutes at 37°C. Subsequently 150 ul NEFA solution B was added and incubated for minutes. Subsequently the optical density (OD) of the sample was measured at 550 nm.
As a control, from each variant 4 pl enzyme solution was incubated with 11 pl HEPES 15 buffer for 60 min at 37°C. Subsequently the amount of free fatty acids was determined as described above. The OD values of this control sample was deducted from the observed OD on each substrate to obtain a corrected activity.
Four different substrates were used, the composition was in general 30 mg lipid, 4.75 ml 50 mM HEPES buffer pH 7, 42.5 pl 0.6 M CaCl2, 200 ul 10% Triton X-100
H202-free. The 30 mg lipid was either phosphatidyl choline (PC), PC with cholesterol ina 9 to 1 ratio, digalactosyl diglyceride (DGDG), or DGDG with cholesterol in a 9 to 1 ratio.
Selection of improved variants
Variants with improved activity towards PC
Those variants that showed an increase in the OD relative to the wild type enzyme when incubated on PC were selected as variants with improved phospholipase activity.
Variants with improved activity towards DGDG
Those variants that showed an increase in the OD relative to the wild type enzyme when incubated on DGDG were selected as variants with improved activity towards
DGDG.
Variants with improved specificity towards DGDG
The specificity towards DGDG is the ratio between the activity towards DGDG and the activity towards phosphatidylcholine (PC). Those variants that showed a higher ratio between DGDG and PC than the wild type were selected as variants with improved specificity towards DGDG.
Variants with improved transferase activity with PC as the acyl donor
The difference in the amount of free fatty acids formed when one incubates an enzyme on PC and on PC with cholesterol is an indication of the amount of transferase activity relative to the amount of hydrolytic activity. Transferase activity will not cause the formation of free fatty acids. The transferase preference is the ratio between the free fatty acids formed when PC is used as a substrate and the free fatty acids formed when
PC with cholesterol is used as a substrate. Those variants that show an increase in the transferase preference and show a higher than wild type activity towards PC were selected as having improved transferase activity.
Variants with improved transferase activity with DGDG as the acyl donor
The difference in the amount of free fatty acids formed when one incubates an enzyme on DGDG and on DGDG with cholesterol is an indication of the amount of transferase activity relative to the amount of hydrolytic activity. Transferase activity will not cause the formation of free fatty acids. The transferase preference is the ratio between the free fatty acids formed when DGDG is used as a substrate and the free fatty acids formed when DGDG with cholesterol is used as a substrate. Those variants that show an increase in the transferase preference and show a higher than wild type activity towards DGDG were selected as having improved transferase activity.
Selected variants
For each of the four selection criteria above a number of variants were selected.
The “wild type” enzyme in this example is A. salmonicida (SEQ ID No. 28).
Variants with improved activity towards PC:
EE LL
Tove
Variants with improved activity towards DGDG:
I LC ons [0
Variants with improved specificity towards DGDG:
R
Jo re fom
Ea a al EC oR [os 100 [00
Variants with improved transferase activity with PC as the acyl donor:
Ll Lia a LLC Lo)
RL LL
I LL CON ve [on [% [5
Variants with improved transferase activity with DGDG as the acyl donor:
RpepG+Chome ow
CloosAl [178 [0
LE 6: Transferase assay Phospholi id:cholesterol
Phospholipid can be replaced by DGDG to provide a transferase assay from a ~ galacolipid. Other acceptors for example, glycerol, glucose, hydroxy acids, proteins or maltose can also be used in the same assay. 300 mg Phosphatidylcholine (Avanti #441601):Cholesterol(Sigma C8503) 9:1 is scaled in a Wheaton glass. 10 ml 50 mM HEPES buffer pH 7.0 is added and stirring at 40 °C disperses the substrate 0,5 ml substrate is transferred to a 4 ml vial and placed in a heating block at 40 °C. 0.050 ml transferase solution is added, also a control with 0.050 ml water is analysed in the same way. The reaction mixture is agitated for 4 hours at 40 °C. The sample is then frozen and lyophilised and analysed by GLC.
Calculation:
From the GLC analysis the content of free fatty acids and cholesterol ester is calculated.
The enzymatic activity is calculated as: % Transferase activity=
A % cholesterol ester/(Mv sterol ester) x 100 .
A % cholesterol ester/(Mv cholesterol ester) +A % fatty acid/(Mv fatty acid) % Hydrolyse activity=
A % fatty acid/(Mv fatty acid) x 100 .
A % cholesterol ester/(Mv cholesterol ester) +A % fatty acid/(Mv fatty acid)
Ratio Transferase/Hydrolyse =% transferase activity/% Hydrolyse activity
Where:
A % cholesterol ester = % cholesterol ester(sample)-% cholesterol ester(control). . A % fatty acid = % fatty acid(sample) - % fatty acid(control).
Transferase assay Galactolipid:cholesterol. 300 mg Digalactosyldiglyceride (DGDG) (purity >95 galactolipids, the DGDG used is purified from wheat lipid. DGDG from Sigma D4651 is also suitable for use):Cholesterol(Sigma) 9:1 is scaled in a Wheaton glass. 10 ml 50 mM HEPES buffer pH 7.0 is added and stirring at 40 °C disperses the substrate. 0,5 ml substrate is transferred to a 4 ml vial and placed in a heating block at 40 °C. 0.050 ml transferase solution is added, also a control with 0.050 ml water is analysed in the same way. The reaction mixture is agitated for 4 hours at 40 °C. The sample is then frozen and lyophilised and analysed by GLC.
Calculation:
From the GLC analysis the content of free fatty acids and cholesterol ester is calculated.
The enzymatic activity is calculated as: % Transferase activity= A % cholesterol ester/(Mv sterol ester) x 100 :
A % cholesterol ester/(Mv cholesterol ester) +A % fatty acid/(Mv fatty acid) % Hydrolyse activity= A % fatty acid/(My fatty acid) x 100 .
A % cholesterol ester/(Mv cholesterol ester) +A % fatty acid/(Mv fatty acid)
Ratio Transferase/Hydrolyse =% transferase activity/% Hydrolyse activity
Where:
A % cholesterol ester = % cholesterol ester(sample)-% cholesterol ester(control).
A % fatty acid = % fatty acid(sample) - 9% fatty acid(control)
EXAMPLE 7: Variants of a lipid acyltransferase for Aeromonas hydrophila (SEQ 1D
No. 26)
Mutations were introduced using the QuikChange™ Multi-Site Directed Mutagenesis kit from Stratagene, La Jolla, CA92037, USA following the instructions provided by
Stratagene.
Variants at Tyr256 showed an increased activity towards phospholipids.
Variants at Tyr256 and Tyr260 showed an increased activity towards galactolipids.
Variants at Tyr265 showed an increased transferase activity with galactolipids as the acyl donor.
The numbers indicate positions on the following sequence: An enzyme from
Aeromonas hydrophila the amino acid sequence of which is shown as SEQ ID No. 26.
The nucleotide sequence is as shown as SEQ ID No. 27.
EXAMPLE 8: Screening of mutants of glycerophospholipid:cholesterol acyltransferase GCAT from Aeromonas salmonicida .
Mutants from point mutations of glycerophospholipid:cholesterol acyltransferase
GCAT from Aeromonas salmonicida were screened for transferase activity using phosphatidylcholine or digalactosyldiglyceride as donor and cholesterol as acceptor with the aim to select mutant with better activity towards digalactocyldiglyceride than phosphatidylcholine.
GCAT mutants were screened for transferase activity using digalactosyldiglyceride(DG) and phosphatidylcholine(PC) as donor and cholesterol as acceptor.
DG (purity >95% digalactosyldiglyceride (DGDG used is purified from wheat lipid.
DGDG from Sigma D4651 is also suitable for use from Signma D4651),) and cholesterol (Sigma C8503) was scaled in the ratio 9 :1 and dissolved in chloroform and evaporated to dryness.
The substate was prepared by dispersing of 3% DG:Cholesterol 9:1 in 50 mM HEPES buffer pH 7. 0,250 ml substrate was transferred to a 3 ml glass with screw lid. 0,025 ml supernatant from fermentation of mutant GCAT was added an incubated at 40 °C for 2 hours. A reference sample with water instead of enzyme was also prepared. Heating the reaction mixture in a boiling water bath for 10 minutes stopped the enzyme reaction. 2 ml 99% ethanol was added and submitted to cholesterol analysis as well as free fatty acid analysis.
Cholesterol assay. 100 pl substrate containing:1.4 U/ml Cholesterol oxidase( SERVA Electrophoresis
GmbH cat. No 17109), 0,4 mg/ml ABTS (Sigma A-1888), 6 U/ml Peroxidase (Sigma 6782) in 0,1 M TRIS,HCI buffer pH 6.6 + 0,5% Triton X 100(Sigma X-100) was 75 incubated at 37°C for 5 minutes. Spl cholesterol sample was added and mixed. The reaction mixture was incubated for further 5 minutes and OD 405m measured. The content of cholesterol was calculated from the analyses of standard solutions of cholesterol containing 0,4mg/ml, 0,3mg/ml , 0,20mg/ml, 0,1mg/ml, 0,05 mg/ml and 0 mg/ml.
Free fatty acid assay.
Free fatty acids in the sample was measured using a NEFA C kit ( WAKO Chemicals
GmbH) 75 pl NEFA reagent A was incubated for 10 minutes at 37 °C. 15 ul enzyme sample . was added and mixed. The reaction mixture was incubated forl0 minutes. 150 pl :
NEFA reagent B was added, mixed and incubated for further 10 minutes and OD 540 nm was measured. Free fatty acid was calculated from standard solutions of 0,4, 0.3, 0.2, 0.1, 0.05 and 0 mM fatty acid.
Transferase assay using pbosphatidylcholine as donor was measured in the same way, but using phosphatidylcholine(Avanti #441601) instead of DG (DGDG).
Transferase activity was expressed as % cholesterol esterified calculated from the difference in free cholesterol in the reference sample and free cholesterol in the enzyme sample.
Hydrolytic activity was expressed as % free fatty acid produced calculated from the difference in free fatty acid in the enzyme sample and free fatty acid in the reference sample. 70 The relative Transferase activity against DG and PC was calculated as % Tpo/Tec.
The transferase activity Tp relative to the hydrolytic activity Hpg on DG for the mutants were calculated: 0.1 x %TDG /386 =0.1 x %TDG x 280 % HDG/280 % HDG x 386
Where 386 = MW for cholesterol and 280 = MW for fatty acid.
Mutants with Tpo>50% and Tpg/Tec>3 and 0.1 x%Tpg/386 >2.5 % Hpg/280 were selected as improved mutants.
The data obtained from the above example can be analysed via statistics to identify and prioritise key sites and/or specific amino acid substitutions which provide the desired activity profile, such as increased ration of Tpg as compared to Tpc. For example, the following robust modeling is proposed:
The information regarding Tec and Tpg is carried by the censored responses max(0,
Tec) and max(0, Tpg). The objective of the study isto identify settings determining Tp >=Tpc, based on the scores for In(1+ Tpo)-In(1+ Tec) with positive values as preference, both in absolute scale and in relative scale compared to a control (native).
The preferred settings are identified based on a binary response (Event, Non-Event), where Event is defined as a preferred response in relation to the scores. A binomial
GLIM model with complementary log-log link, based on the empirical data structure without prior information included, analyses the binary responses. See the following reference for details of how to perform the statistical analysis: proc LOGISTIC in
SAS Institute Inc., SAS/STAT® User's Guide, Version 6, 4.Ed, Vol.2, Cary, NC: SAS
Institute Inc., 1989. [Variants with | Vaziants with | Variants with enhanced Tpo/ Hoo increased Tpo/Tpc | enhanced ~~ DGDG | activity transferase activity
Toe
N8OP,G,orE YIT9E,R, N,Q
K22E,K S310Q,HorS N215G
G40 L S3E,A,G,KMY, L210D,H,R,E, A, Q,P,N,K, GR,
N87R,D,E.M R,P,N,T,orQ T,W,LVorS
Y117 A, N, E, H, | -318 R, S, E, H, Q, | N80 G
T NorD Y30L
QI82K, T N215 1, G, V, R or | N87 G
M209 K,M Y HI180L T
L210N K82S M209 Y
R211G R211D, Tor G
N215H S18G,MorT
Y2301 G40RorM -318Y,HorS N88 W
N215H N87C,D,R,Eor G 1210D,QorT
E 309S, QorR
H180KorQ
N8N,RorD
L210 G, I, H, E,
M,S, W,V,AR,
N,
S310A,P, T,H, M,
K,orG : vii2C
Y30G,LL,S,E,
M,AorR
V290R,E,Hor A
Q289RorN
K22E
G40L
Y179V
M209L,K,M
L211 G,Q,KorD
Y230V
S310P
YI179R
H180 T
Q289 Tor D
G40Q,LorV
N88 W
N87RorD
EXAMPLE 9: Selection of improved mutants of glycerophospholipid:cholesterol acyltransferase GCAT from 4eromonas salmonicida.
The “parent” enzyme in this example is 4. salmonicida (SEQ ID No. 28). 32 positions of GCAT from Aeromonas salmonicida (230 Tyr, 182 Lys, 3 Thx, 157
Asp, 310 Thr, 318 Gly, 309 Glu, 17 Leu, 111 Trp, 117 Tyr, 179 Tyr, 118 Leu, 215
Asn, 22 Lys, 290 Val, 289 Gln, 285 Met, 18 Ser, 23 Met, 180 His, 284 Lys, 181 Asn, 209 Met., 210 Leu, 211 Arg, 40 Gly, 81 Pro,112 Val, 80 Asn, 82 Lys, 88 Asn, 87 Asn were screened according to the experimental outline in Example 8.
Based on the results from the screening and the three selection criteria the following mutants listed in the table 1 were selected.
Table 1
Position Amino acid T,pC T,DG TDGTPC HPC H, DG 210 GLN 10,3 59,7 59 0,0 0,0 215 GLY 15,1 55,8 4,5 3,1 1,0 215 LEU 19,4 51,9 3,3 43 1,1 215 TYR 21,3 68,0 3,9 43 1,8 215 ARG 16,2 62,1 4,7 55 2,1 215 VAL 14,7 61,6 52 35 1,7 215 HIS 5,7 50,1 10,9 42 1,3 215 ASN 9,4 474 6,2 40 1,2
EXAMPLE 10: Selection of specific amino acid regions of interest for mutation of the glycerophospholipid:cholesterol acyltransferase GCAT from Aeromonas salrmonicida.
From the pfam alignment (alignment 2; FIGURE 56) and overlay of the P10480 model and 1TVN all amino acids in regions surrounding the glycerol molecule in the active site of 1IVN were selected and used for defining regions of specific interest (loops). (Numbers refer to the amino acids in the P10480 mature sequence (SEQ ID No. 2):
Thr 20- Arg 41 (Loop 1, L1)
Tle 77- Leu 89 (Loop 2, L2)
Leu 118 — Asp 127 (Loop 3, L3)
Gly 146- Val 176 (Loop 4, L4)
Glu 208 — Trp 287 (Loop 5, LS)
The intervening regions (IVR) were named accordingly:
Alal-Asp 19 (IVRI])
Phe 42 — Lys 76 (IVR2)
Asp 90 — Tyr 117 (IVR3)
Ala 128 — Asn 145 (IVR4)
Ser 177 — Ala 207 (IVRS5)
Asp 288 — His 317 (IVR6)
The following table summarizes the allocation of preferred positions for mutation of the glycerophospholipid:cholesterol acyltransferase GCAT from Aeromonas salmonicida. The results are based on experimental outlines as set out in Example 8- 10.
P10480 Preferable | 10 A Preferred amino acid | sites to regions for positions produce methods of the (SEQ ID No | variants invention 2) with increased
Too/ Tec wri Te ors. |_ a
Y 30
FE EE A EE EE
77-89 N80, N87, | N80, P81, K82, | Loop 2
N88 N87, N88
IVR3 | 90-117 Y117, will, VI112,{IVR3
V112, Al14,Y117
Will, IVR3 & 10A
All4, from active site.
Toop |TiE7 | jos |]
Rd [sas
Toopd [186176 | ____ [Pis6
IVRS | 177-207 N181i, Y179, H180,|IVRS
Q182, N1i81
H180, IVR5S & 10A
Y179 from active site.
Loop5 | 208-287 M209, M209, L210, | Loops
L210, R211, N2I5,
R211, K284, M285, |Loop 5 & 10A
N215, Q289, V290 from active site.
Y230 wear lo 289.1 [VR6
S310, -318
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.
Claims (44)
1. A method of producing a variant glycolipid acyltransferase enzyme comprising: (a) selecting a parent enzyme which is a lipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, LF, Y, H,Q T,N,MorS; (b) modifying one or more amino acids to produce a variant lipid acyltransferase; (c) testing the variant lipid acyltransferase for transferase activity, and optionally hydrolytic activity, on a galactolipid substrate, and optionally a phospholipid substrate and/or optionally a triglyceride substrate; (d) selecting a variant enzyme with an enhanced activity towards galactolipids compared with the parent enzyme; and optionally (¢) preparing a quantity of the variant enzyme.
2. A method according to claim 1 wherein the method comprises testing the variant lipid acyltransferase for: (i) transferase activity from a galactolipid substrate, and (ii) transferase activity froma phospholipids substrate; and selecting a variant enzyme, which when compared with the parent enzyme, has an enhanced ratio of transferase activity from galactolipids compared with phospholipids. 70
3. A method according to claim 2 wherein the ratio of transferase activity from galactolipids compared with phospholipids is at least 3.
4. A method according to any one of the proceedings claims comprising testing the variant lipid acyltransferase for: (a) transferase activity from a galactolipid substrate, and (b) hydrolytic activity ona galactolipid substrate; and selecting a variant enzyme with an enhanced ratio of transferase activity from galactolipids compared with its hydrolytic activity on glycolipids, compared with the parent enzyme.
: PCT/IB2004/004378
5. A method according to claim 4 wherein the enhanced ratio of transferase activity on galactolipids compared to hydrolytic activity on galactolipids is at least 1.5.
6. A method according to any one of the preceding claims wherein one or more of the following amino acid residues identified by alignment with SEQ ID No. 2 is modified compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
7. A method according to any one of the preceding claims wherein the parent enzyme comprises an amino acid sequence as shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45, or an amino acid sequence which has at least 70% identity therewith.
8. A method according to any one of the preceding claims wherein the parent enzyme is an enzyme which comprises the amino acid sequence shown as SEQ ID No. 2 and/or SEQ ID No. 28.
9. A method according to any one of claims 1 to 5 wherein the parent lipid acyltransferase enzyme is encoded by any one of the following nucleotide sequences: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID
No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46 or a nucleotide sequence which has at least 75% or more identity with any one of the sequences shown as SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46. AMENDED SHEET
: PCT/IB2004/004378
10. A method according to any one of the preceding claims wherein Preferably, the X of the GDSX motifs L.
11. A method according to any one of the preceding claims wherein the method further comprises one or more of the following steps: structural homology mapping or sequence homology alignment.
12. A method according to claim 11 wherein the structural homology mapping comprises one or more of the following steps: a) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 52; b) selecting one or more amino acid residue within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53); and ¢) modifying one or more amino acids selected in accordance with step (b) in said parent sequence.
13. A method according to claim 11 wherein the structural homology mapping comprises one or more of the following steps: a) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 52: b) selecting one or more amino acids within a 10A sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 53); ¢) determining if one or more amino acid residues selected in accordance with step (b) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and d) modifying one or more amino acids selected in accordance with step (b), excluding conserved regions identified in accordance with step (c) in said parent sequence.
14. A method according to claim 11 wherein the sequence homology alignment comprises one or more of the following steps: i) selecting a first parent lipid acyltransferase; AMENDED SHEET
: PCT/IB2004/004378 identifying a second related lipid acyltransferase having a desirable activity; aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; identifying amino acid residues that differ between the two sequences; and modifying one or more of the amino acid residues identified in accordance with step (iv) in said parent lipid acyltransferase.
15. A method according to claim 11 wherein the sequence homology alignment may comprise one or more of the following steps: selecting a first parent lipid acyltransferase; identifying a second related lipid acyltransferase having a desirable activity; aligning said first parent lipid acyltransferase and the second related lipid acyltransferase; identifying amino acid residues that differ between the two sequences; determining if one or more amino acid residues selected in accordance with step (iv) arc highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and modifying one or more of the amino acid residues identified in accordance with step (iv) excluding conserved regions identified in accordance with step (v) in said parent sequence.
16. A method according to any one of the preceding claims comprising modifying one or more of the following amino acid residues: -318, N215, L210, S310, E309, H180, N80, V112, Y30X (where X is selected from A, C,D, E,G, H,, K, L, M,N, P, Q, R, ST, V, or W), V290, Q 289, K22, G40, Y179, M209, L211, K22, P81, N87, Y117, N181, Y230X (where X is selected from A, C,D, E,G, H,, K,L, M,N, P, Q,R,S, T, V, or W), Q182.
17. A method according claim 16 comprising modifying one or more of the following amino acid residues: -318, N215, L210, E309, H180, N&O.
18. A method according to any one of claims 1-15 comprising modifying one or more of the following amino acid residues: -318, N215, L210, $310, E309, H180, N&O, AMENDED SHEET
: PCT/IB2004/004378 V112, Y30X (where X is selected from A, C, D,E, G,H,L K,L,M,N,P, Q,R,S, T, V, or W), V290, Q 289, K22, G40, Y179, M209, L211, K22, P81, N87, Y117, N18l, Y230X (where X is selected from A, C,D,E, G,H, , K,L, M,N, P,Q, R,S, T, V, or Ww), Q182, S3, K82.
19. A method according to any one of claims 1-15 comprising modifying one or more of the following amino acid residues: Y230X (where X is selected from A, C, DD, E, G, H,1LK,L,M,N,P,Q,R,S, T, V,or W), S310, Y179, H180, Q289, G40, N88, N87.
20. A method according to any one of claims 1-15 comprising modifying one or more of the following amino acid residues: Y179, N215, L210, N80, Y30X (where X is selected from A,C,D,E,G, H,, K,L,M,N, P,Q, R, S, T, V, or W), N&7.
21. A method according to any one of claims 1-15 comprising modifying one or more of the following amino acid residues: Y179, N215, L210, N80, Y30X (where X 1s specifically selected from A, C,D, E, G, H, LK, L, M, N, P, Q,R,S, T,V,orW), N87, H180, M209, R211, S18X (where X is specifically selected from A, C, D, E, F, H, LK L MNP QR, T,WorY), G40, N88, N87.
22. A variant glycolipid acyltransferase enzyme characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I. F, Y, H, Q. T, N, M or §, wherein the variant has an enhanced activity towards galactolipids compared with the parent enzyme and wherein the variant enzyme comprises one Or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
23. A variant glycolipid acyltransferase enzyme according to claim 22 wherein the variant enzyme comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 16, SEQ ID No. 18, SEQ ID No. 20, SEQ ID No. 22, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28, SEQ ID No. 30, SEQ ID No. 33, SEQ ID No. 34, SEQ ID No. 36, SEQ ID No. 37, SEQ ID No. 39, AMENDED SHEET
. PCT/IB2004/004378 SEQ ID No. 41, SEQ ID No. 43 or SEQ ID No. 45 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
24. A variant glycolipid acyl transferase according to claim 22 or claim 23 wherein the enzyme comprises one or more amino acid modifications at any one or more of the following amino acids: -318, N215, L210, S310, E309, H180, N80, V112, Y30X (where X is selected from A, C,D.E,G, H, L K,L, M,N, P, Q,R, §, T, V, or Ww), V290, Q 289, K22, G40, Y179, M209, L211, K22, P81, N87, Y117, N18l1, Y230X (where X is selected from A, C,D,E,G, H, LK, L, M,N, P,Q, R, 5, T, V, or Ww), V290, N87, Q182.
25. A variant glycolipid acyl transferase according to claim 24 wherein the enzyme comprises one or more amino acid modification at any one or more of the following amino acid residues: -318, N215, L210, E309, H180, N80.
26. A variant glycolipid acyl transferase according to claim 22 or claim 23 wherein the enzyme comprises one or more amino acid modifications at any one or more of the following amino acids: -318, N215, L210, S310, E309, H180, N80, V112, Y30X (where X is selected from A, C,D, E, G, H, , K,L, M,N, P, Q, R, S, T, V, or W), V290, Q 289, K22, G40, Y179, M209, L211, K22, P81, N87, Y117, N181, Y230X (where X is selected from A, C, D, E, G, H, L K,L, M,N, P,Q, R, §, T, V, or W), V290, N87, Q182, S3, S310, K82, E309.
27. A variant glycolipid acyl transferase according to claim 22 or claim 23 wherein the enzyme comprises one or more amino acid modifications at any one or more of the following amino acids: Y230X (where X is selected from A, C, D, E, G,HLK,L, M,N,P,Q,R,S, T,V, or W), S310, Y179, H180, Q289, G40, N88, N&7.
28. A variant glycolipid acyl transferase according to claim 22 or claim 23 wherein the enzyme comprises one or more amino acid modifications at any one or more of the following amino acids: Y179, N215, L210, N80, Y30X (where X is selected from A,C,D,E,G,H,LK,L,M,N,P,Q,R,S, T, V, or W), N87. AMENDED SHEET
: PCT/IB2004/004378
29. A variant glycolipid acyl transferase according to claim 22 or claim 23 wherein the enzyme comprises one or more amino acid modifications at any one or more of the following amino acids: Y 179, N215, L210, N80, Y30X (where X is specifically selected from A, C,D,E,G, H,L K,.L,M,N, P,Q, R, S, T, V, or W), N87, H180, M209, R211, S18X (where X is specifically selected from A, C,D, E, F, H,, K,L, M, N,P,Q.R, T, WorY), G40, N88, N87.
30. A variant glycolipid acyl transferase according to claim 22 wherein the parent lipid acyltransferase enzyme is encoded by any one of the following nucleotide sequences: SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46 or a nucleotide sequence which has at least 75% or more identity with any one of the sequences shown as SEQ ID No. 7, SEQ ID No. §, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 15, SEQ ID No. 17, SEQ ID No. 19, SEQ ID No. 21, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No.27, SEQ ID No. 29, SEQ ID No. 31, SEQ ID No. 32, SEQ ID No. 35, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 42, SEQ ID No. 44 or SEQ ID No. 46.
31. A variant glycolipid acyltransferase enzyme according to any one of claims 22-30 wherein the variant enzyme has an enhanced ratio of activity on galactolipids to either phospholipids and/or triglycerides when compared with the parent enzyme.
32. A variant glycolipid acyltransferase according to any one of claims 22-31 wherein the variant enzyme has a higher galactolipid transferase activity compared with its galactolipid hydrolytic activity compared with the parent enzyme.
33. A variant glycolipid acyltransferase enzyme according to any one of claims 22-32 wherein the variant enzyme is an enzyme which comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 2 or SEQ ID No. 28 except for AMENDED SHEET
) PCT/IB2004/004378 one or more amino acid modifications at any one or morc of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
34. Use of a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 in a substrate for preparing a lyso-glycolipid, for example digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG) by treatment of a glycolipid (e.g. digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG)) with the variant lipolytic enzyme according to the present invention or obtained by a method according to the present invention to produce the partial hydrolysis product, i.e. the lyso-glycolipid.
35. Use according to claim 34 wherein the substrate is a foodstuff.
36. A method of preparing a foodstuff the method comprising adding a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 to one or more ingredients of the foodstuff.
37. A method of preparing a baked product from a dough, the method comprising adding a variant glycolipid acyltransferase enzyme according to any one of claims 22- 33 or obtained by the method according to any one of claims 1-21 to the dough.
38. Use of a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 in a process of treating egg or egg-based products to produce lysophospholipids.
39. A process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 so as to hydrolyse a major part of the polar lipids (e.g. phospholipid and/or glycolipid). AMENDED SHEET
¢ PCT/IB2004/004378
40. Use of a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 in a process for reducing the content of a phospholipid in an edible oil, comprising treating the oil with said variant lipolytic enzyme so as to hydrolyse a major part of the phospholipid, and separating an aqueous phase containing the hydrolysed phosphc:ipid from the oil.
41. Use of a variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21 in the bioconversion of polar lipids (preferably glycolipids) to make high value products, such as carbohydrate esters and/or protein esters and/or protein subunit esters and/or a hydroxy acid ester.
42. An immobilised variant glycolipid acyltransferase enzyme according to any one of claims 22-33 or obtained by the method according to any one of claims 1-21.
43. A method according to claim 1 substantially as herein described with reference to and as illustrated in any of the examples and accompanying figures and sequence listings.
44. A variant glycolipid acyltransferase according to claim 22 substantially as herein described with reference to and as illustrated in any of the examples and accompanying figures and sequence listings. AMENDED SHEET
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0330016.7A GB0330016D0 (en) | 2003-12-24 | 2003-12-24 | Method |
PCT/IB2004/000655 WO2004064537A2 (en) | 2003-01-17 | 2004-01-15 | Method for the in situ production of an emulsifier in foodstuff |
GBGB0415999.2A GB0415999D0 (en) | 2003-12-24 | 2004-07-16 | Proteins |
US10/911,160 US20050196766A1 (en) | 2003-12-24 | 2004-08-02 | Proteins |
PCT/IB2004/004378 WO2005066347A1 (en) | 2003-12-24 | 2004-12-23 | Proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200605158B true ZA200605158B (en) | 2008-04-30 |
Family
ID=30776521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2006/05158A ZA200605158B (en) | 2003-12-24 | 2006-06-22 | Proteins |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP2010142243A (en) |
CN (2) | CN103275944B (en) |
AT (1) | ATE462011T1 (en) |
DE (1) | DE602004026229D1 (en) |
DK (1) | DK1704236T3 (en) |
GB (3) | GB0330016D0 (en) |
HK (1) | HK1106953A1 (en) |
NZ (1) | NZ547085A (en) |
RU (2) | RU2377307C2 (en) |
ZA (1) | ZA200605158B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114958800B (en) * | 2022-06-24 | 2023-08-25 | 北京脉道生物药品制造有限公司 | Taq DNA polymerase mutant capable of tolerating blood or blood product inhibition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1193314B1 (en) * | 1997-04-09 | 2004-10-20 | Danisco A/S | Use of lipase for improving doughs and baked products |
WO2000005396A1 (en) * | 1998-07-21 | 2000-02-03 | Danisco A/S | Foodstuff |
ES2345973T3 (en) * | 2001-07-11 | 2010-10-07 | Cognis Ip Management Gmbh | LIPASE / ACILTRANSPHERASE FROM CANDIDA PARPSYLOSIS. |
CA2535147A1 (en) * | 2003-08-11 | 2005-05-19 | Codexis, Inc. | Improved glucose dehydrogenase polypeptides and related polynucleotides |
-
2003
- 2003-12-24 GB GBGB0330016.7A patent/GB0330016D0/en not_active Ceased
-
2004
- 2004-07-16 GB GBGB0415999.2A patent/GB0415999D0/en not_active Ceased
- 2004-07-16 GB GBGB0416023.0A patent/GB0416023D0/en not_active Ceased
- 2004-12-23 RU RU2006126654/13A patent/RU2377307C2/en not_active IP Right Cessation
- 2004-12-23 CN CN201310150130.9A patent/CN103275944B/en not_active Expired - Fee Related
- 2004-12-23 NZ NZ547085A patent/NZ547085A/en not_active IP Right Cessation
- 2004-12-23 DK DK04806537.9T patent/DK1704236T3/en active
- 2004-12-23 CN CN200910206577A patent/CN101676390A/en active Pending
- 2004-12-23 RU RU2006126715/13A patent/RU2377300C2/en not_active IP Right Cessation
- 2004-12-23 DE DE602004026229T patent/DE602004026229D1/en active Active
- 2004-12-23 AT AT07017066T patent/ATE462011T1/en not_active IP Right Cessation
-
2006
- 2006-06-22 ZA ZA2006/05158A patent/ZA200605158B/en unknown
-
2008
- 2008-01-17 HK HK08100607.7A patent/HK1106953A1/en not_active IP Right Cessation
-
2010
- 2010-02-04 JP JP2010022832A patent/JP2010142243A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2010142243A (en) | 2010-07-01 |
RU2377307C2 (en) | 2009-12-27 |
DE602004026229D1 (en) | 2010-05-06 |
RU2006126654A (en) | 2008-01-27 |
CN103275944B (en) | 2016-12-07 |
GB0416023D0 (en) | 2004-08-18 |
HK1106953A1 (en) | 2008-03-20 |
ATE462011T1 (en) | 2010-04-15 |
DK1704236T3 (en) | 2018-01-08 |
CN101676390A (en) | 2010-03-24 |
GB0330016D0 (en) | 2004-01-28 |
RU2006126715A (en) | 2008-01-27 |
GB0415999D0 (en) | 2004-08-18 |
RU2377300C2 (en) | 2009-12-27 |
NZ547085A (en) | 2009-11-27 |
CN103275944A (en) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004312215B2 (en) | Proteins | |
EP1762622B1 (en) | Method for the in situ production of an emulsifier in a foodstuff | |
EP1791933B1 (en) | Enzymatic oil-degumming method | |
US7807398B2 (en) | Method of using lipid acyltransferase | |
RU2518345C2 (en) | Proteins | |
US7906307B2 (en) | Variant lipid acyltransferases and methods of making | |
JP2007516717A6 (en) | protein | |
US8030044B2 (en) | Lipid acyltransferases | |
ZA200605158B (en) | Proteins | |
AU2006203065B2 (en) | Method | |
ZA200610468B (en) | Lipolytic enzyme. Uses thereof in the food industry | |
MXPA06007423A (en) | Proteins |